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ABSTRACT 
Using the potential of immune regulatory cell populations for cellular therapy 
constitutes an attractive tool to obliterate imbalances of immune responses in 
inflammatory disorders. In this context, adoptive transfer of mesenchymal stromal cells 
(MSCs) represents a relatively novel approach and its impact on the immune system 
has not been completely clarified. In this thesis we aimed to study the effects of MSCs 
on key immune cell types, which led us amongst others to investigate regulatory T-cells 
(TRegs), and myeloid cells.  
We show that MSCs utilize the anti-oxidative, immune regulatory enzyme 
hemeoxygenase-1 (HO-1) for suppressing T-cell activation directly and for inducing 
TRegs (=indirect T-cell suppression). An inflammatory milieu generated by alloreactive 
T-cells led to the so-called ‘licensing’ of the MSCs boosting their regulatory capacity. 
Interestingly, HO-1 expression was substantially diminished during this process and its 
functions were taken over by other (up-regulated) molecules such as cyclooxygenase-2 
thereby highlighting (functional) MSC plasticity. 
Most MSC-based trials lack a systemic immune monitoring, which is key for 
interpreting the in vivo effects of MSCs. Performing a comprehensive flow cytometry-
based immune screening in patients with acute graft-versus-host disease (aGVHD), 
treated with either third-party MSC or placebo infusions (in a double-blinded fashion), 
we were - most importantly - able to further corroborate the notion that MSCs function 
in vivo partly by promoting TReg-subsets. Thereby, our data underscores the need for 
accompanying extensive immune analyses to better comprehend such “bench-to-
bedside” approaches. Accordingly, we carried out thorough, laboratory investigations 
when we were the first to apply MSCs in a patient with treatment-refractory 
hemophagocytic lymphohistocytosis. Upon MSC infusion we could observe an 
increase of the immune modulating cytokine interleukin (IL)-10 in the serum and a 
preferential appearance of regulatory type 2 macrophages in the patients’ bone marrow. 
Altogether, this data confirmed previous findings from in vitro and animal model 
studies regarding the MSCs’ impact on myeloid cell populations. Driven by these 
observations we sought out to assess whether MSCs induce so-called myeloid derived 
suppressor cells (MDSCs) in aGVHD patients. Although we did not find an MSC-
associated effect, we were the first to identify monocytic CD14+HLA-DRlow/neg MDSCs 
accumulating after allogeneic hematopoietic transplantation. We characterized their 
suppressive function (via indoleamine-2,3-dioxygenase) and established a significant 
association with inflammatory cytokines and aGVHD. In fact, our data indicates that 
MDSCs are part of an immune regulating feedback mechanism that is activated during 
hyper-inflammations (such as in aGVHD). 
Overall, our results indicate that immune regulatory populations play a decisive role in 
various inflammatory diseases and MSCs could boost their responses. Furthermore our 
work suggests that combining basic and translational research is pre-requisite for 
understanding the MSCs’ multifaceted interactions and for optimizing their clinical use. 
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1 INTRODUCTION 
A functioning and balanced immune system is key to our existence. It efficiently 
protects us from invading pathogens, eliminates aberrant (malignant) cells and 
constantly evolves and adapts to new challenges. Cellular defects or dysfunctions in 
various diseases, but also iatrogenic conditions unhinge this tightly regulated system. 
This can render afflicted persons defenseless against pathogens and can drive the 
system out of balance leading to autoreactive, potentially life threatening processes. 
Besides traditional, drug-based approaches adoptive cellular therapy has emerged as an 
auspicious strategy. It aims to replace deficient or diseased parts of the immune system 
respectively to reestablish balance by introducing potent immune regulators into an 
unbalanced system. Cellular therapy’s most successful representation is at the same its 
most holistic form: the allogeneic hematopoietic stem cell transplantation (alloHSCT).  
AlloHSCT allows the replacement of an entire hematopoiesis and immune system and 
permits the cure for various hematological diseases. On the other hand, it exposes us to 
problems of unique complexity as we need to cope (a) with (transient) 
immunodeficiency, (b) a reconstituting immune system, and (c) potential rejection 
reactions (against the graft or the host). A plethora of innovative drugs and an emerging 
number of cell-based approaches have been introduced for the treatment of the 
complications following alloHSCT. As yet, studies based on adoptive T-cell transfer 
have dominated the field, such as virus-specific T-cells to boost host defense, donor 
lymphocyte infusion to ensure tumor eradication, and infusion of ex vivo expanded 
regulatory T-cells (TRegs) in order to attenuate the reactivity of the newly transplanted 
immune system against the host. In some settings natural killer (NK)-cell infusion was 
utilized for promoting anti-tumor immunity. However, cells other than lymphocytes are 
steadily gaining momentum, when it comes to restore immune homeostasis in rejection 
reactions and autoimmunity, with mesenchymal stromal cells (MSCs) being the most 
prominent representative and subject of this thesis. 
Since their initial introduction ten years ago MSCs’ safety and efficacy has been shown 
in several pre-clinical and clinical studies for the treatment of various inflammatory 
conditions (e.g. multiple sclerosis (MS), rheumatoid arthritis, and sepsis). However, it 
is still scarcely understood how exactly MSCs impact the immune system and how they 
exert their immune regulatory effects in vivo. We were in the privileged position to 
study the interaction of human MSCs with the innate and adaptive immune system at 
the ‘bench’ and then to try to validate our findings at ‘the bedside’ by analyzing unique 
sample collections from patients that had received MSC treatment. 
The aim of all adoptive cell therapies is to exert very specifically the desired effect 
without systemic toxicity and without compromising the immune system in other ways. 
A profound understanding of the underlying immunologic mechanisms is sine qua non 
to improve cellular therapies and to allow further individualization. Much knowledge 
can be undeniably gained from in vitro and animal-models, however effective cellular 
therapy necessitates thorough evaluation of patient samples and clinical data for 
comprehending the in vivo processes in one of the most complex biologic systems – the 
human. 
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2 MESENCHYMAL STROMAL CELLS 
2.1 DISCOVERY 
Nowadays, multipotent mesenchymal stromal cells (MSCs) are widely known for their 
regenerative and immune regulatory properties. In the 60s of the last century 
Friedenstein et al. identified a small subpopulation of colony-forming unit fibroblasts 
(CFU-F) among bone marrow cells that are capable to form ectopic bone tissue [2, 3]. 
These cells could be easily distinguished from the rest of the bone marrow cells based 
on their plastic adherence, a spindle-shaped appearance, and a rapid expansion [3]. In 
humans, MSCs constitute about 0.001 to 0.01% of the bone marrow mononuclear cells 
isolated from Percoll gradient [4] and their number steadily decreases over lifetime [5]. 
MSCs can virtually be isolated from all mammalian connective tissues [4, 6] but to date 
bone marrow still remains the primary source while cord blood [7] and adipose tissue 
[8] gain more and more importance. 
2.2 DEFINITION OF MSCs 
As yet, no specific marker has been identified for MSCs. In 2006 the International 
Society of Cellular Therapy (ISCT) proposed a panel of so-called minimal criteria in 
terms of required function and surface antigens for classifying candidate cells as MSCs 
[9]. MSCs need to be plastic adherent under standard culture conditions and must 
display in vitro trilineage multipotency by differentiating into bone, fat, and cartilage. 
The markers CD73 (ecto-5’-nucleotidase), CD90 (Thy-1) and CD105 (endoglin, SH2) 
have to be expressed on over 95% of the cells. Additionally, MSCs lack myeloid 
markers (CD11b, CD14), hematopoietic progenitor and endothelial cell marker (CD34 
(mucosialin)), the common leukocyte antigen (CD45), B-cell markers (CD19 or 
CD79a) and human leukocyte antigen (HLA)-DR [9]. 
 
 
 
 
 
 
  
Figure 1: Phenotypical characterizations of MSCs. MSCs are defined by the expression of 
CD73, CD90, CD105 and the absence of CD14, CD20, CD34 and CD45. This representative 
FACS analysis shows the characteristic expression profile of these markers (= red) in human 
bone marrow derived MSCs (grey= isotype control). 
    3 
 
Adhesion molecules  
 
Immunoglobulin 
superfamily 
ALCAM (CD166), ICAM-1 (CD54), ICAM-2 (CD102),  
ICAM-3 (CD50), NCAM (CD56), HCAM (CD44), VCAM 
(CD106) 
 Integrins (ITG) 
ITG-α1 (CD49a), ITG-α2 (CD49b), ITG-α3 (CD49c), ITG-α5 
(CD49e), ITG-α6 (CD49f), ITG-αV (CD51), ITG-β1 (CD29), 
ITG-β3 (CD63), ITG-β5 
  Transmembrane superfamily Tetraspanin (CD9) 
Toll-like receptors TLR1, TLR2, TLR4, TLR5, TLR6, TLR9 
Chemokine Receptors  
 
C-C chemokine receptor 
(CCR) 
CCR1, CCR2, CCR4, CCR6, CCR7, CCR8, CCR10 
 
C-X-C chemokine receptor 
(CXCR) CXCR1 CXCR2, CXCR4, CXCR5, CXCR6 
 
CX3 chemokine receptor 
(CXCR1) 
CX3CR1 
Growth factor receptors EGFR, FGFR, IGFR, PDGFR, TGFβRI, TGFβRII, NGFR 
Cytokine receptors  
 Interleukin (IL) receptors IL-1R, IL-3R, IL-4R, IL-6R, IL-7R, Prolactin receptor (PRLR) 
 
Prostaglandin (PG) E 
receptors E prostanoid (P)1, EP2, EP3, EP4 
 
Interferon (IFN)-γ-, tumor 
necrosis factor (TNF) -
receptors 
IFN-γR, TNFRI (CD120a), TNFRII (CD120b) 
Ligands  
 
Programmed death (PD) 
ligands 
PD-L1 (CD274), PD-L2 (CD273) 
 
 
 
Notch ligand Jagged 1 
Signaling receptors  
 Wnt receptors Fz2, Fz3, Fz4, Fz5, Fz6 
 Notch Notch 1, 2, 3,  
Proteins STRO-1, MUC18 (CD146) 
Table 1: Receptors and molecules that have been identified to be expressed on MSCs.  
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Based on their assumed capacity for self-renewal, the 
term mesenchymal stem cell was introduced in the 1980s 
[5] and became widely popular in the 1990s [10]. Stem 
cells per definition differentiate under the appropriate 
conditions into various cell types and replenish lifelong 
tissues with new cells. According to their plasticity and 
differentiation versatility, they are classified as totipotent, 
pluripotent and multipotent stem cells (Figure 2).  
MSCs retain for up to 40 cell divisions their trilineage 
multipotency [11]. However, not all individual MSCs 
exhibit the same level of multipotency. MSCs seem to 
rather comprise a mixture of cells being at different 
maturation levels, of which many are solely mono- or 
bipotent [12]. Furthermore, excessive expansion of MSCs 
in vitro has been associated with a loss of differentiation capability, telomere shortening 
along with genetic or epigenetic modifications, resulting in senescence and apoptosis 
[13-15]. It is therefore still an ongoing debate whether MSCs truly represent stem cells. 
Currently, the term ‘multipotent mesenchymal stromal cells’ more and more replaces 
the potentially equivocal term ‘multipotent mesenchymal stem cells’ [11].  
2.3 IMMUNOGENICITY 
MSCs were considered an attractive tool for adoptive cell therapy early on. This is 
partially owed to a key immunological feature: their so-called immune-privilege, which 
means that they do not elicit a specific immune response when infused in HLA-non-
identical hosts.  
HLA-Class I and II are the two major classes of HLA-molecules on cell surfaces that 
present peptides of processed antigens to immune cells. HLA-Class I molecules present 
peptides of cytosolic antigens that have been synthesized within the cell. If these self-
antigens are a flawless presentation of ‘self’, they inhibit NK-cell mediated toxicity. 
However, if the presented self-antigens exhibit alterations e.g. due to viral infections, 
tumors or if HLA-Class I is down-regulated in malignant diseases, cytotoxic T-cells 
(CTLs) along with NK-cells are activated and ideally eliminate the aberrant cell. HLA-
class II molecules are expressed at high densities on phagocytizing cells and antigen 
presenting cells (APCs). Alloantigens are taken up, processed, and presented to 
immune cells thereby initiating their activation leading to potent antigen-specific 
immune responses.  
Un-stimulated MSCs are positive for HLA-Class I molecules and can therefore inhibit 
NK-cell mediated lysis [16]. Furthermore, un-stimulated MSCs are negative for HLA-
Class II molecules [17]. This remarkable characteristic allows cell-transfer across 
HLA-barriers and makes them a bona fide tool for an “off the shelf” cell therapy [18, 
19].  
  
Stem Cells 
 
Totipotent 
e.g. Zygote 
 
Pluripotent 
e.g. embryonic stem cell 
 
Multipotent 
e.g. hematopoietic stem 
cell 
Figure 2: Differentiation 
capability of stem cells. 
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2.4 CROSSTALK OF MSCs WITH THE IMMUNE SYSTEM 
MSCs exhibit numerous immune regulatory mechanisms interfering with the innate and 
the adaptive immune system (Table 2). To describe all the different populations and 
immune compartments in detail is beyond the scope of this introduction. Therefore, this 
chapter focuses mainly on the aspects that have been addressed within this thesis.  
The majority of the observed immune regulatory effects can be attributed to a plethora 
of enzymes and secreted immune modulatory factors encompassing cytokines, 
chemokines and interleukins (Figure 3). Most data on the interaction of MSCs with 
immune cells originate from preclinical studies, which did not always produce 
consistent results. Over time it became apparent that these mostly in vitro observed 
effects depend on the origin of MSCs (tissue as well as species), condition and duration 
of culture and the activation status of responder cells as well as MSCs.  
 
 
Recent data suggests that an inflammatory environment, in particular abundance of 
cytokines such as interferon (IFN)-γ, tumor necrosis factor (TNF)-α, Interleukin (IL)-
1α and IL-1β, activates MSCs [33]. This process is called “licensing” [34] and results 
in an increased immune suppressive potency due to an elevated expression of immune 
regulatory molecules (Table 3) such as indoleamine-2,3-dioxygensase (IDO) or 
cyclooxygenase-2 (COX-2) [35, 36]. In fact, it can be speculated that MSC-“licensing” 
is part of physiological negative-feedback mechanisms that are activated for preventing 
the exacerbation of inflammatory responses. Actually, there are even efforts to integrate 
the MSCs’ responsiveness to in vitro “licensing” (with IFN-γ and TNF-α) in the 
evaluation process for screening the most potent MSCs to be used in clinical 
approaches [33]. 
 
  
Innate immune system  [11] 
 Complement [20, 21] 
 TLR-signaling [11] 
 Macrophages [22] 
 Dendritic cells [23, 24] 
 Neutrophils [25] 
 Mast cells [26] 
 NK-cells [27, 28] 
Adaptive immune system   
 T-cells  [29] 
 TH1-TH2 Balance [30] 
 Induction of TRegs [31] 
 B-cells  [32] 
Table 2: Overview over the identified interactions of MSCs with the different parts of the 
innate and adaptive immune system. 
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Immune modulatory molecules B7-H1 / PD-L1 / CD200 / CD274 
Cytokine / chemokine receptors CD119 / IFN-γ receptor, CXCR3, 4, 5, CCR7 
Adhesion molecules CD54, CD106 
DNAM ligands CD112, CD115 
NKG2D ligands 
Macrophage inflammatory complex A/B,  
UL binding protein 1, 2, 3 
Notch receptors Jagged-1 
TLR TLR-3, TLR-4 
Cytokines IDO, COX-2 
Table 3: Upregulated molecules and cytokines upon inflammatory licensing [33]. 
 
Lymphoid cells were the first to be identified as preferential targets of MSC-mediated 
effects. Soluble factors (e.g. IL-10 and prostaglandin (PG) E2 [37, 38]), as well as cell-
to-cell contact-dependent mechanisms (interaction of programmed death (PD)-1 with 
its respective ligands (PD-L1, PD-L2) [39]) are both involved in T-cell inhibition. 
MSCs suppress in a dose-dependent fashion the proliferation, IFN-γ production, and 
cytotoxicity of activated CD4+ and CD8+ T-cells [24, 40, 41].  
Induction of T-cell apoptosis as mean of MSC-mediated T-cell suppression is still 
under debate [42, 43]. However, activation induced cell death (AICD) of T-cells is 
shown to be decreased as a consequence of the attenuated T-cell activation in the 
presence of MSCs. Furthermore, MSCs indirectly diminish T-cell responses by 
preventing maturation and thereby antigen priming function of the main APCs: the 
dendritic cells (DCs) [44-47].  
The different types of differentiated T-cells regulate the immune response. Increased 
frequencies of IL-17-producing T-cells have been associated with various inflammatory 
diseases. MSCs were shown to prevent the differentiation of naïve CD4+ T-cells into 
pro-inflammatory Th17-cells [48, 49]. Furthermore, by inducing TRegs, MSCs amplify 
their immune regulatory capacity. They directly induce TRegs by expressing immune 
modulatory enzymes or molecules such as HLA-G [50] and hemeoxygenase-1 (HO-1) 
[31]. Furthermore, by e.g. secretion of IL-10 and PGE2, MSCs skew other cell types 
(e.g. monocytes and DCs) towards regulatory phenotypes capable of TReg induction [24, 
47]. Recently, we confirmed the positive effect of MSCs on TRegs induction ex vivo in 
patients receiving a third-party MSC infusion [51].  
Similar to the inhibitory effect on T-cells, co-culturing MSCs with (CpG 
oligonucleotide 2006, anti-immunogloblin (Ig) antibodies, IL-2, IL-4, IL-10) stimulated 
B-cells leads to an inhibition of B-cell proliferation, impaired Ig-secretion, and lack of 
CXCL-12 driven B-cell chemotaxis in vitro [32]. Furthermore, MSCs impair the 
maturation of B-cells into Ig-producing plasma cells [52]. Candidate molecules for 
mediating these B-cell suppressive effects are tumor growth factor (TGF)-β1, 
hepatocyte growth factor (HGF), PGE2 and IDO [32]. These observations have recently 
been challenged by studies showing that MSCs actually support survival, proliferation 
and differentiation of B-cells [53, 54]. The effect on B-cells is a typical example of how 
the type of effect elicited by MSCs varies depending on the activation status of 
responder cells (in this case B-cells) and MSCs: MSCs present in a mixed lymphocyte 
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culture can inhibit IgG, IgA and IgM production, an effect that is abrogated, if B-cells 
are stimulated with CD40L [55]. Furthermore, as Rasmusson et al. demonstrated, the 
grade of MSC activation is critical. There seems to be a direct correlation of the 
potency of the stimuli present in the co-culture and the MSC mediated effect. Under 
low stimulation with lipopolysaccharide (LPS) or viral antigens MSCs increase Ig-
production by B-cells, but have an Ig-reducing function in the presence of high levels 
of the aforementioned stimuli [54]. 
 
 
 
 
 
Figure 3: Impact of MSC-derived soluble factors on T-cells and myeloid cells. MSCs 
express and secrete a plethora of molecules that have direct inhibitory effects on myeloid and 
T-cells. Furthermore, MSCs induce an immune regulatory phenotype in both, lymphoid and 
myeloid cells. Inflammatory cytokines such as IFN-γ and TNF-α elicit an inflammatory 
licensing of MSCs, which leads to the up-regulation of inter alia IDO and COX-2 thereby 
further potentiating their immune regulatory potency.  
 
Two key cell populations for anti-viral and anti-tumor immune defense are the CD8+ 
CTLs and NK-cells . Since MSCs express only low levels of HLA-Class I molecules 
(“missing self”) and several NK-cell activating ligands (ligands for NKG2D e.g. 
ULBPs, MICA and ligands for DNAM-1 PVR, Nectin-2), they should be targeted by 
NK-cells [27]. Whether MSCs are lysed or not by NK-cells depends on (1) the NK-cell 
pre-activation status [16, 28, 56, 57] and (2) the tissue origin of MSCs [58], which 
additionally also determines the elicited death pathways (TRAIL by fetal MSCs or 
FasL by adult MSCs) [59]. Then again, it has been shown that MSCs lead to the down-
regulation of activating NK-receptors (NKp30, NKp44, NKG2D) [28] and impact 
negatively by COX-2 [57] and IDO [60] the IFN-γ production [24], proliferation [28] 
and cytoxicity of NK-cells.  
Peptides of cytosolic processed antigen of virus-infected cells and tumor cells presented 
by HLA-Class I lead to the activation and proliferation of CD8+ CTLs. CD8+ CTLs 
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play a pivotal role for the elimination of these diseased cells by releasing e.g. cytotoxic 
granules and pro-apoptotic surface receptors [61, 62]. Despite HLA-Class I expression, 
allogeneic MSCs exhibit a low susceptibility to CTL-mediated lysis and do not lead to 
CTL-activation, even if pulsed with synthetic peptide [61].  
The inhibiting role of MSCs seems to be limited to the initial stimulation phase of 
CTLs, where they inhibit formation of antigen-specific CTLs and target cell lysis [63, 
64]. MSCs do not have an effect on the cytotoxic phase [47, 61, 64] and interfere only 
to a small extent with the lysis mediated by viral-antigen-specific memory CTL in vitro 
and in vivo [47, 63]. 
Despite this in vitro evidence, if MSCs impair anti-viral responses in vivo has not been 
completely resolved. In patients that were treated with MSCs for steroid refractory 
graft-versus-host disease (GVHD) a higher incidence of cytomegalovirus (CMV) 
infections in GVHD affected organs was observed [65]. However, compared to a 
historic control MSC treated GVHD patients did not experience a higher rate of viral 
infections and exhibited a sufficient anti-viral response [66]. 
MSCs have a (1) chemotactic as well as an (2) immune regulatory effect on myeloid 
cells. MSCs attract macrophages and monocytes in case of tissue damage and/or 
mobilize them from the bone marrow by secreting monocyte chemotactic protein 1 
(MCP-1) in response to generalized inflammatory reactions as seen during sepsis [67]. 
This potentially serves two effects: first, macrophages and monocytes boost the 
clearance of invading organisms and cell debris, 
which is a prerequisite for wound healing [68, 
69]. Next, MSCs can regulate inflammation by 
shifting the type of cytokines produced by 
myeloid cells. Induction of IL-10 by e.g. IDO 
[70] or PGE2 [22] can lead, as convincingly 
demonstrated in a murine sepsis model, to a 
significantly better control of inflammation and 
finally survival [22]. In a recent study it has been 
shown that MSCs induce a myeloid derived 
suppressor cell (MDSC)-like phenotype in 
monocyte-derived DCs. These cells were immune suppressive and capable of skewing 
conventional T-cells towards a tolerogenic immunophenotype [71].  
Taken together, MSCs exert a multifaceted immune regulatory response in various cells 
of the immune system. Overall, they seem to induce a more tolerogenic milieu, which 
is even more potentiated in an inflammatory environment. MSCs elicit inhibiting 
effects, directly by e.g. impairing inflammatory immune responses or indirectly by 
inducing immune regulatory populations such as TRegs and alternative type monocytes. 
2.5 MSCs AS A THERAPEUTIC TOOL  
As discussed above MSCs exhibit a potent capacity for immune regulation and tissue 
regeneration. MSCs can be isolated with relative ease from healthy donors and quickly 
multiplied in vitro. Together with their low immunogenicity, they can be transplanted 
across HLA-barriers and can be used as a third-party off-the-shelf product to treat 
patients. This section will briefly describe the different current applications of MSCs.  
Monocytes can be polarized by a 
the surrounding environment in an 
acute inflammatory phenotype 
(M1), which plays an important role 
in host defense for example by 
phagocytosis of bacteria, and an 
alternative type of monocytes (M2), 
which is immune-regulatory and 
important for maintaining immune 
tolerance as well as tissue repair.  
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2.5.1.1 Regenerative medicine 
Since their differentiation capability into various tissues was the first well-defined 
feature of MSCs, their clinical application was initially focused on tissue replacement 
and regeneration. MSCs secrete many factors that promote wound healing and 
restoration of physical barriers [72]. Furthermore, in murine models, it was 
demonstrated that MSCs quickly home to sites of tissue injury [73, 74]. Infusion of 
MSCs was for example successfully used to substitute defective bone tissue in 
osteogenesis imperfecta patients [75]. Osteogenesis imperfecta is a congenital bone 
disorder characterized by the defective production of Type I collagen. This defect leads 
amongst others to frequent bone fractures resulting in bone deformities. In a seminal 
study, fetal MSCs were transplanted in utero in a human female fetus with severe 
osteogenesis imperfecta, manifesting already with multiple intrauterine bone fractures. 
The engraftment of the transplanted MSCs was successful despite existing immune 
competence of the host [76].  
A further scope of the regenerative intended application of MSCs constitutes a very 
common disease of the western world: myocardial infarction. Myocardial infarction is 
accompanied by scaring of the affected heart tissue leading to diminished contractility 
of the heart muscle and hence a less effective pumping function. In pig models of 
myocardial infarction, it was shown that MSCs infused in the affected coronary artery 
had a beneficial effect on the recovery of heart function [77]. MSCs release a broad 
array of trophic and immune regulatory molecules (thereby limiting inflammation of 
the damaged tissue) but may also stimulate the endogenous cardiac stem cells 
recruitment and differentiation [78, 79].  
Recently, the research in tissue engineering has focused on integrating bioartificial 
scaffolds to potentiate tissue regeneration. Maccarini et al. demonstrated the great 
potential this approach holds by using stem cells grown on a scaffold to replace a 
tracheobronchial airway tube in a patient after its own trachea had been removed due to 
tumor resection [80]. 
2.5.1.2 Immunomodulation 
The discovery of the immune regulating functions of MSCs heralded their era as a 
potential cellular therapy for (hyper-) inflammatory diseases. In fact, in vitro evidence 
suggests that MSCs migrate towards 
inflammatory cytokines and in 
response to complement namely the 
component 1 subcomponent q (C1q) 
[81], C3a and C5a [20]. This feature 
might indicate their tropism towards 
the site of damage and inflammation. 
This is very useful in terms of their 
migration towards the preferential 
areas of action upon infusion.  
MSCs are currently evaluated for the 
treatment of several autoimmune 
disorders [11], such as autoimmune 
arthritis [82] and autoreaction-driven 
Hemophagocytic lymphohistiocytosis (HLH) 
is a rare autoimmune disease. Two forms exist: 
the primary, familial HLH, which is based on 
genetic mutations and the secondary, reactive 
form, which is triggered by viruses, bacteria and 
parasites. 
HLH patients present with hepatosplenomegaly 
and fever, hyperactivation of T-cells and 
macrophages, which results in a cytokine storm. 
This leads to the hyperactivation of 
macrophages and increased production of TNF-
α, IL-6, ferritin and ultimately the phagocytosis 
of leukocytes accompanied by the typical 
cytopenia.  
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Haploidentical means that 
the donor and recipient are 
genetically identical for half 
of the HLA molecules 
neurological diseases amongst others amyotrophic lateral sclerosis and MS. In animal 
models of MS and amyotrophic lateral sclerosis the beneficial effect of MSCs has been 
demonstrated [43, 83] and currently, adoptive transfer of MSCs is evaluated in clinical 
trials [84]. Furthermore, MSCs have been anecdotally used as rescue therapies or for 
“bridging” a desolate inflammatory situation (until allogeneic hematopoietic stem cell 
transplantation (alloHSCT) could be performed), in which standard treatment was 
ineffective e.g. in rare autoimmune diseases such as HLH [85] and autoimmune 
enteropathy [86]. 
2.5.1.2.1 MSCs in hematopoietic stem cell transplantation  
In the bone marrow niche, stromal cells (including MSCs) support hematopoiesis. MSC 
function can be impaired after chemotherapy [87] leading to a prolonged reconstitution 
harboring an increased risk for infections. Therefore the hope for an accompanying 
infusion of in vitro expanded human MSCs together with hematopoietic stem cells 
(HSCs) was to achieve a faster reconstitution. This is especially of interest for patients 
that receive HSCs from a haploidentical donor or cord blood, which are regularly 
associated with delayed engraftment (see section 3 of this thesis). Indeed, the first 
studies in transplanted breast cancer patients showed an 
improved reconstitution after alloHSCT if MSCs were 
co-infused [88]. Equally important, no adverse effects 
were registered [89]. Also in haploidentically-
transplanted patients, infusion of MSCs led to quicker 
lymphocyte recovery [90]. In pediatric patients a co-infusion of in vitro expanded 
MSCs failed to prevent graft rejection, however MSCs appeared to prevent another life 
threatening complication after alloHSCT: the development of acute GVHD (aGVHD) 
[91]. Severe aGVHD is one reason for the high morbidity and mortality after HSCT 
(see section 3.5.3). In short, aGVHD is characterized by hyperactivated T-cells of the 
graft, which react against healthy tissue of the host. Steroid treatment constitutes the 
first-line therapy to which about 50-60% of all patients respond [92]. The response to 
treatment correlates with severity of disease and patients with milder GVHD show a 
better response rate (> 60%), than severe GVHD (Grade IV 33%) [92]. However, in the 
event of steroid unresponsiveness, aGVHD can become treatment-resistant and is 
associated with high morbidity and mortality (up to 90%) [93]. 
Cellular therapy has emerged as a promising tool for the complications (including 
GVHD) that occur during the post-transplant period. One of them is the adoptive 
therapy of MSCs. Le Blanc et al. were the first to administer cryopreserved, third-party 
MSCs for severe aGVHD with gut and liver involvement in a pediatric patient that did 
not respond to conventional treatment. The infusion of haploidentical MSCs from the 
patients’ mother led to a remarkable clinical improvement and durable complete 
remission. Importantly, no toxic side effects were observed [94]. 
The adoptive transfer of MSCs still remains a relatively novel experimental approach to 
treat aGVHD. Despite the vast knowledge gained during the last decade many 
questions remain unresolved and observations are not always coherent. In contrast to 
the unequivocal beneficial effects demonstrated in clinical phase I and II trials in 
aGVHD carried out at European academic facilities, a commercial, large phase III 
study by Osiris (Therapeutics Inc Columbia, MD, USA) failed the reach the primary 
end-point of the study. It is important to stress out that in this Osiris-led study MSCs of 
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only few donors were heavily expanded, which is a major contrast to the studies carried 
out at academic houses, where MSCs from one donor and at low passages were 
transferred into one patient [95]. Low passages seem to be a prerequisite for a more 
effective MSC function [65]. In the future, it will be of great importance to develop, 
integrate, and harmonize protocols, which will allow us the identification of the most 
potent, e.g. in terms of immune regulation, MSCs for clinical application. Consensus 
regarding MSC selection criteria, culturing protocols and expansion rate would 
furthermore result in a higher comparability among studies.  
2.5.2 Safety 
Every novel treatment has to be critically reviewed in regards of any occurring adverse 
events and in comparison to established standard treatment. MSCs exhibit low toxicity 
and no adverse side effects have been reported during or right after MSC administration 
irrespective of treatment indication [89, 94, 96, 97]. 
Since MSCs are a relatively new cellular therapy, long-term risks are still very poorly 
evaluated in large cohorts. No spontaneous formation of ectopic bone or cartilage 
formation was shown for the infusion of autologous human MSCs together with 
autologous HSCs [88, 89] and even more importantly no ectopic tumor formation was 
observed for MSCs [98]. 
In particular, aside from an elevated risk of infections due to impaired immune 
responses, any immune suppressive treatment might lead to increased relapse rates in 
patients that underwent HSCT to treat a malignant disease. As described above MSCs 
have been shown to impact CD8+ CTLs [61] and NK-cells [27, 28]. Both are critical for 
the prevention of (malignant) diseases and virus-clearance, but on the other hand 
activated CTLs also drive GVHD [61]. In vitro evidence shows that although MSCs 
suppress the primary alloantigen-induced proliferation and IFN-γ production by human 
peripheral T-cells, they seem to be able to exert a selective T-cell control. They do not 
impair expansion of CMV and Epstein-Barr virus (EBV) pentamer-specific T-cells nor 
the proliferation or cytolytic-killing in established CMV- and EBV-specific CTLs [63]. 
2.5.3 Engraftment 
One yet not completely resolved puzzle is the way of redistribution of MSCs upon 
infusion respectively engraftment. In animal models a quick distribution to the lungs 
was shown immediately after infusion [99]. In patients with cirrhosis that were infused 
with 111-In-oxine labeled MSCs, cells accumulated initially 
in the lungs, and then redistributed to spleen and liver, where 
they could be detected up to 10 days [100]. In case of non-
human primates, MSCs were detected in gastrointestinal 
tissue, lung, liver, kidney, thymus and skin after several 
months at a range of 1x103 to 2.7 x 104 cell equivalents per 
microgram of DNA [101]. If tissue was injured prior to 
infusion for example due to irradiation, even higher rates (up 
to 10%) were to be observed [102]. In HSCT-patients, MSC 
long-term engraftment was extremely low and scarce as assessed in autopsies [103-
105]. Overall, these observations indicate that MSCs do not integrate into host tissue 
thereby exerting long-term activity. MSCs appear to mediate their effects in a rather 
Engraftment is the 
successful integration 
of transplanted cells in 
the recipient bone 
marrow niche. In stem 
cell transplantation this 
refers to the time point 
when the transplanted 
stem cells produce new 
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“hit-and-run” fashion. Upon infusion MSCs might represent “only” the trigger for 
initiating a cascade of immunological events that lead to a more tolerogenic immune 
profile (=tolerogenic immune memory) and thereby indirectly shift (or even restore) the 
balance of immunological processes. 
2.6 CONCLUSION 
Compared to other cellular therapies like HSCT discussed in the next chapter, the 
adoptive transfer of MSCs for inflammatory diseases is a very novel approach. Despite 
the repetitively documented clinical responses, mechanisms by which MSCs exert in 
vivo their immune regulatory effect have not been fully deciphered not allowing us to 
predict which patient would benefit the most from such treatment or to monitor 
treatment efficacy at a cellular level. In order to develop more individualized protocols 
and to achieve the most effective MSC therapy possible, a profound understanding is 
therefore indispensable. Due to the lack of convincing preclinical models (as rodent 
MSCs are vastly different from human MSCs), basic research on MSCs has overall 
occurred in vitro, and was furthermore confused by the big inter-study variances. For 
the future, synchronizing manufacturing and culturing protocols would immensely help 
to transfer the knowledge gained in vitro to the clinical setting. We are of the opinion 
that it represents a key step for ensuring that the beneficial effects of MSCs stay in the 
limelight and are not overshadowed by potential inconsistent results. 
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3 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
Hematopoietic stem cell transplantation (HSCT) is the most successful and routinely 
used form of cellular immunotherapy [106]. It allows replacing a failing or diseased 
hematopoiesis and immune system with a new, healthy one. Furthermore, it represents 
the only curative option for many hematological malignancies [107] with patients 
suffering from leukemia and lymphoma accounting for the largest patient cohort.  
3.1 HISTORY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION 
HSCT was initially developed for two reasons: (1) to treat patients with immune 
deficiencies and inherited anemia and (2) as a rescue therapy after myeloablative cancer 
therapy. In 1951 the seminal study by Lorenz et al. 
demonstrated for the first time in lethally irradiated mice 
that the transplantation of syngeneic as well as autologous 
bone marrow allows reconstitution of a sufficient 
hematopoiesis that ensures survival [108]. This 
reconstitution can be attributed to a small number of HSCs 
in the bone marrow that is characterized by the expression of 
the cell surface protein CD34, which seems to function as a 
cell-to-cell adhesion factor. Furthermore, CD34 might also 
impact cell proliferation and maturation but its function has 
not yet been completely understood [109]. These CD34+ 
HSCs regenerate primitive progenitors, which reproduce less-differentiated precursors 
and finally develop into mature blood cells. Since peripheral blood cells exhibit a 
limited life span, a constant replenishment of the peripheral blood pool is important to 
maintain sufficient blood cell numbers throughout the body.  
The first HSCT in humans was performed in the late 1950ies in a patient with end-stage 
leukemia [110]. Even though hematological recovery was achieved in some 
transplanted patients, the outcome of the early transplantations remained poor. A study 
investigating the survival of patients that received transplants between 1958 and 1968 
showed that in 1970 only three out of 203 patients were still alive [111]. This can partly 
be attributed to the advanced stages of disease of the treated patients, but also due to the 
limited understanding of the immunological processes initiated by the transplantation of 
a whole immune system. 
3.2 HLA-SYSTEM 
The discovery of the importance of the HLA-system by J. J. van Rood and J. Dausset in 
the 1960s was one of the most decisive developments towards an individualized stem 
cell therapy and made transplantation of third-party stem cells feasible. HLA-molecules 
are expressed on the surface of cells and present peptides recognized by immune cells 
allowing the distinction from self- and non-self-antigens [112, 113]. This plays an 
arbitrative role for the whole function of the immune system in every human being, but 
also explains many of the immunological adversities faced upon alloHSCT.  
HLA-genes consist of three main classes that are structurally and functionally different. 
All nucleated cells express HLA-Class I genes however at varying levels. HLA-Class I 
Myeloablation 
describes the situation 
in which the bone 
marrow is completely 
depleted of bone 
marrow cells by high 
doses of chemotherapy 
or irradiation. This 
leads to a complete 
failure of hematopoiesis 
and is therefore lethal.  
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Cancer immunosurveillance: 
F.M. Burnet and L. Thomas 
postulated the hypothesis that 
cancer cells are targeted and 
recognized by the immune 
system namely lymphocytes. 
molecules present peptides of processed cytosolic antigen and are essential for 
regulating the NK-cell mediated cytotoxicity and for triggering CD8+ CTLs. Twenty 
different genes exist, the most important ones are HLA-A, -B, and C.  
HLA-Class II genes present endo- and phagocytized extracellular antigens and are 
normally expressed by specialized immune cells as e.g. professional APCs, B-cells, 
activated T-cells, and thymic epithelial cells. The class II genes encode for the alpha 
and beta polypeptide chains of the class II molecules. The most significant ones are 
HLA-DR, HLA-DQ, and HLA-DP. So far, HLA-Class III plays a minor role in 
transplantation and is involved in immunity by expression complement factors and 
cytokines.  
Since each person has a specific combination for his or her histocompatibility 
complexes, it is essential to thoroughly evaluate the HLA-region for matching 
recipients with adequate donors. Taken together, the rate of rejection, occurrence and 
severity of GVHD as well as the grade of delay in immune reconstitution is 
proportional to the degree of mismatch between donor and recipient [114, 115].  
3.3 IMMUNOLOGICAL ERADICATION OF TUMOR CELLS 
Although patients undergoing alloHSCT are overall well pretreated and at best disease 
free or exhibit minimal residual disease, it is always possible that some tumor cells 
survive the therapy leading to the relapse of disease. This is especially true for stem cell 
diseases such as leukemia. Cancer stem cells are quiescent, metabolically inactive cells 
that remain in G0-state and do not proliferate [116]. As most chemotherapeutic agents 
act almost exclusively on proliferating cells, some malignant stem cells might 
successfully evade even lethal doses of total body 
irradiation (TBI) and chemotherapy. 
Every healthy, well-functioning immune system 
recognizes and targets malignant cells to a certain 
degree (concept of cancer immunosurveillance) [117, 
118]; however soon after alloHSCT was introduced, 
it became apparent that the transplantation of a third 
party donor-derived graft results in lower relapse rates (35 percent) [119] than the 
transplantation of a syngeneic or autologous graft (40 to 75 percent) [120]. In 
subsequent studies, it was elucidated that the potential to target and eliminate residual 
tumor cells (graft-versus-tumor (GVT) effect) was mediated by the alloreactivity of the 
allogeneic graft against the host. An allogeneic graft consequently does not only 
recognize cancer cells as malignant (based on the expression of tumor antigens), but 
also as foreign and therefore kills them even more efficiently [121]. This effect is 
predominantly conveyed through host-reactive co-transplanted donor-derived CTLs 
that react against recipient HLA-complexes. [122]. Increasing evidence suggests that in 
certain haploidentical donor-recipient constellations observed GVT effect can also be 
mediated by NK-cells [123].  
In a seminal study, H.J. Kolb demonstrated that the infusion of additional donor derived 
lymphocytes so-called DLI in the post-transplant period can potentiate respectively 
boost the GVT effect [124]. This has laid the foundation to an effective immunological 
targeting of cancer cells by the transplanted immune system. It revolutionized cancer 
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Leukapheresis is a process in 
which white blood cells are 
filtered out of the blood 
stream and collected while the 
remaining blood components 
are returned to the donor. 
therapy respectively changed the perception of conditioning therapy allowing the 
introduction of a non-myeloablative conditioning therapy (see section 3.4.2). 
3.4 HSCT PROCEDURE 
In principle a successful HSCT follows three consecutive phases (1) a suitable graft has 
to be selected first. Depending on underlying disease, the transplant can be the (A) 
patient’s own stem cells (autologous), (B) stem cells from genetically identical siblings 
(syngeneic) or (C) third-party derived stem cells (allogeneic). (2) Before receiving the 
transplant, each patient has to undergo a therapy that creates the right conditions 
(‘conditioning therapy’) in the host to receive the transplant. (3) Transplantation is 
followed by a post-transplant period characterized by immunodeficiency until the new 
immune system reconstitutes resulting in a healthy, functioning immune system. 
3.4.1 Graft and sources of stem cells 
The primary graft source for the first HSCTs was bone marrow. Bone marrow cells are 
collected under local or general anesthesia by repeated aspiration at the posterior iliac 
crest. It still remains the source of choice for pediatric patients. The discovery of G-
CSF and its mobilizing function of CD34+ cells from 
the bone marrow into the peripheral blood have 
resulted in the predominate use of peripheral mobilized 
stem cells (PMSCs) in adults. Sufficient numbers of 
PMSCs are easily collected via the antecubital veins by 
leukapheresis and can be subsequently frozen in liquid 
nitrogen (< -160°C) until further use. Storage of HSCs 
in liquid nitrogen warrants high viability after thawing and facilitates e.g. the usage of 
autologous HSCs that are collected prior to conditioning therapy. Another positive 
feature of PMSCs is a quicker engraftment and immune reconstitution as compared 
with bone marrow grafts [125].  
Umbilical cord blood constitutes the third source of graft and was first used in 1988 for 
alloHSCT between matched siblings in a child with Fanconi’s anemia [126]. Cord 
blood is rich in HSCs and contains more naïve, immature cells [127] as well as 
immunosuppressive TRegs [128]. Potentially due to this multitude of immune regulatory 
and naïve cells (=more tolerogenic milieu), cord blood transplants cause less GVHD 
and require less restrictive HLA-matching, however in contrast to autologous 
transplants a GVT effect is still observed. Despite these premises the success of 
treatment still increases with better HLA-matching and increasing numbers of HSCs 
[129]. Since volume of cord blood and number of HSCs is limited, double-unit cord 
blood transplants are regularly used in order to achieve sufficient HSC numbers 
suitable for transplantation in adults. In recent studies the co-transplantation of cord 
blood HSC with HLA-haploidentical peripheral stem cells [130] as well as the ex vivo 
expansion of cord-blood stem cells [131] are under investigation. 
3.4.2 Conditioning therapy 
For each patient that undergoes HSCT a specific regimen depending on underlying 
disease and co-morbidities is chosen that conditions or prepares the body for receiving 
the new immune system. Conditioning therapy comprises three goals: (A) the reduction 
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Opportunistic infections are 
infections by pathogens that 
would not cause infections in a 
healthy host but take advantage 
of the in immune-compromised 
situations of the patient e.g. 
after HSCT but also AIDS. 
of the underlying disease, (B) the depletion of the recipient’s bone marrow from the 
(diseased) hematopoietic system making room for the new immune system, as well as 
the (C) immunosuppression to avoid immune-rejection especially in alloHSCT. 
Traditionally, conditioning therapy encompassed a combination of TBI, chemotherapy 
with cyclophosphamide, which was thought to constitute the main tumor eradicating 
effect of the treatment. This combination is rather harsh and accompanied with high 
toxicity that led to the limited application of HSCTs to younger individuals with no 
severe co-morbidities.  
The discovery of the aforementioned curative potential of the GVT effect paved the 
way for a reduced intensity conditioning (RIC). RIC does not primarily aim to exert an 
anti-cancer effect but rather aims to prepare the immune system for the transplantation. 
It therefore solely relies on the immunological eradication of residual cancer cells after 
transplantation [132]. RIC avoids the high morbidity and mortality caused by early 
organ toxicity of a standard conditioning regimens thereby allowing alloHSCT in 
elderly patients with comorbidities. It has however been associated with a higher 
relapse rate, indicating the importance of a good remission status prior to 
transplantation [133]. 
3.4.3 Reconstitution of the immune system 
The reconstitution of the immune system in terms of 
versatility, rapidity and quality determines the 
success of alloHSCT and cancer eradication [134]. 
The profound immunodeficiency as prevalent in this 
post-transplant phase holds many severe risks for the 
patient: (1) occurrence of (opportunistic) infections 
(see Section 3.5.2 of this chapter), (2) recurrence of 
the underlying malignant disease due to a missing 
cancer immunosurveillance and (3) long term development of secondary malignancies 
[135].  
Reconstitution is influenced by many factors and events: they can occur (1) before 
transplantation namely conditioning regimen and type of GVHD prophylaxis, (2) at the 
time point of transplant (type of transplantation, choice of graft, manipulation of any 
sort, the degree of histocompatibility (HLA, mHAg, NOD/CARD15 [136])) or (3) after 
HSCT (presence and grade of GVHD, relapse, infections [137-139]). 
The first cells that reconstitute within the first months are the innate immune cells such 
as neutrophil (mostly first 30 days) and myeloid cells, which are important cells to fight 
bacterial infections. Interestingly, host derived macrophages are mostly not impacted 
by conditioning therapy and persist in the tissue. They are replaced by donor-derived 
macrophages over time [140]. Reconstitution has been predominantly studied in terms 
of numerical alterations; however decisive for e.g. host defense is the efficient function 
of the cells. In spite of increasing numbers, neutrophils can be inoperable due to 
insufficient chemotaxis and phagocytic-bactericidal function for several months [141].  
The rapid post-transplant recovery of NK-cells is mostly attributed to an expansion of 
cytokine producing CD56brightCD16- NK-cells and takes about 3 months [142].  
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T- (at least 4 months) and B-cells (at least 9-12 months) take much longer to 
reconstitute and the complete regeneration of the T- and B-cell compartments can take 
1-2 years after HSCT.  
In adults the first subtype of T-cells that expands in response to IL-2, IL-7 and IL-15 in 
the post-HSCT period are the memory T-cells, particularly CD8+ T-cells [143, 144]. 
Overall, CD8+ T-cells exhibit a quicker reconstitution than CD4+ T-cells [137] leading 
to an inversed CD4+/CD8+ T-cell ratio compared to healthy persons in the first months 
[145, 146]. Both residual host memory T-cells that survived conditioning therapy as 
well as donor memory T-cells in a non-T-cell-depleted graft can give rise to this 
population [147]. Memory T-cells react against previously encountered pathogens such 
as herpes viruses (CMV and EBV) and enter more easily tissue than naïve T-cells 
[148]. However, in order to respond adequately to new immune challenges towards 
pathogens and tumor antigens, the naïve T-cell repertoire needs to be reconstituted 
(neothymopoiesis). Since for a complete regeneration, the whole T-cell ontogeny is 
thymus dependent, involution of thymus due to age seems to play a decisive role. This 
seems to be especially true for CD4+ T-cells [149] and as a consequence elderly 
patients never manage to fully restore the peripheral naïve T-cell receptor repertoire 
[150, 151]. The population of these lymphocytes leaving the thymus is named recent 
thymic emigrants (RTE) and can nowadays be monitored according to the signal-joint 
T-cell receptor rearrangement or T-cell receptor excision circles (TREC) [152]. Low 
TREC levels have been associated with the aforementioned diminished thymus 
function due to age, but also by impaired function during opportunistic infections and 
after alloreactive immune responses in the course of GVHD. A dysfunctional thymus 
entails an even enhanced GVHD disease activity, since it results in an incorrect 
selection of T-cell clones respectively fails to effectively deplete auto-reactive T-cells. 
Humoral immune responses require a functioning B-cell lineage encompassing B-cell 
derived plasma cells and memory B-cells. B-cells reconstitute within the first 6 to 9 
months [153] and seem to be dependent on a functioning, immaculate bone marrow 
micro environment. Infiltration of the bone marrow by alloreactive T-cells (GVHD) as 
well as GVHD immunosuppressive treatment results in a diminished B-cell 
reconstitution [139]. Furthermore, similar to the T-cell receptor (TCR) repertoire also 
the immunoglobulin variety (B-cell antibody) seems to be decreased after 
transplantation [154].  
The reconstitution of the immune system is the most decisive step towards cure. A 
profound understanding of involved underlying processes as well as associated immune 
impairments will help to adequately cope with many of the subsequently described 
complications, which originate from an incompetent immune system.  
3.5 COMPLICATIONS AFTER HSCT 
3.5.1 Early complications 
Early negative effects of HSCT are largely associated with the toxic side effects of the 
conditioning radio- and chemotherapy and the diminished immune function. In the 
following paragraphs, some of the most common early complications are described.  
Mucositis is a one of the most prevalent problems in patients after HSCT. It is caused 
by conditioning therapy (= direct tissue damage) and also constitutes a common side 
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effect of the widely used immunosuppressive agent methotrexate, which preferably 
targets the fast dividing cells of the mucosa. Oropharyngeal mucositis is very painful 
regularly requiring opioid-based pain medication. Intestinal mucositis often necessitates 
parenteral substitution of fluids and calories. Keratinocyte growth factor (KGF) has 
been used to treat and/or prevent mucositis in some studies showing mixed results 
[155]. Interestingly, KGF seems to possess a positive effect on thymus function in 
terms of enhanced thymopoiesis [156].  
A very severe, early complication caused by endothelial damage is the hepatic veno-
occlusive disease (VOD) also known as sinusoidal obstruction syndrome. It originates 
from the hepatotoxic effects of the conditioning regimen, which affects the sinusoidal 
capillary endothelium. Toxic metabolites that are retained in the liver facilitated by e.g. 
preexisting liver impairment or due to interactions with other drugs lead to an 
obstruction of hepatic circulation that causes hepatomegaly, fluid retention and 
jaundice. Treatment is very difficult and prevention remains the main goal [157]. 
Defibrotide, which is a deoxyribonucleic acid derivative, has shown some promising 
results in the treatment of VOD [158].  
HSCT-associated thrombotic microangiopathy (TMA) is characterized by anemia, 
thrombocytopenia, schistozytes and elevated lactate dehydrogenase. It is associated 
with high mortality (75%) [159]. In contrast to other treatment related adverse events, 
the intensity of treatment seems to play a minor role in the incidence of TMA. Certain 
drugs e.g. calcineurin inhibitors, sirolimus [160], viral as well as fungal co-infections, 
HLA-mismatched donor grafts [161] and aGVHD [162] seem to drive it. Endothelial 
dysfunction causes microangiopathic hemolytic anemia and platelet consumption. The 
most decisive therapeutic action is to immediately and completely abrogate calcineurin 
inhibitors and change of GVHD prophylaxis respectively therapy to e.g. mTOR-
inhibitors. The beneficial effect of plasmapheresis and application of thrombolytics has 
been described in some cases [163].  
An early onset of hemorrhagic cystitis is associated with direct toxic effects of the 
conditioning regimen. Clinical presentation can range from microscopic asymptomatic 
hematuria, but also very painful, heavy hemorrhage of the entire urine tract has been 
observed. A later onset is mostly mediated by viral infections (mostly BK 
polyomavirus, but also adenovirus and CMV) and aGVHD. Hemorrhagic cystitis is 
normally treated by consequent irrigation and supportive platelet infusions. 
3.5.2 Infections 
The post-transplant period is coined by an increased risk of infections. It reflects the 
immune compromised situation of the patient as well as the consequences of intensive 
pretreatment during conditioning and iatrogenic immunosuppression. The disruption of 
protective anatomical barriers as skin and mucosa by radio-chemotherapy, mucositis 
and GVHD together with the usage of plastic catheters further facilitate the entry of 
pathogens into the body.  
The first thirty days after HSCT are characterized by functional asplenia, absent B- and 
T-cells and most predominantly neutropenia. Neutrophils represent the first line of 
defense against invading pathogens. Patients are therefore prone to bacterial infections, 
candida and Aspergillus species as well as Herpes simplex virus (HSV). These 
pathogens often originate from the patient’s endogenous gastrointestinal flora, which 
    19 
led to the prophylactic usage of antibiotics for the so-called selective intestinal 
decontamination. However, the benefit of this approach has become heavily disputed, 
since it seems to disrupt the microbial balance of the gut impacting the onset of 
aGVHD (see following section GVHD).  
With rising numbers of neutrophils the incidence of bacterial and fungal infections 
decreases and infections that are related to the impaired T- and B-cell function 
dominate. T-cells are vital to prevent viral infections as well as invasive fungal 
infections. HSCT patients are prone to develop viral infections namely CMV, EBV, 
adenovirus, BK polyomavirus and respiratory viruses. In addition to newly acquired 
infections, viruses that reside permanently (and under previous immunologic control) in 
the patients’ tissues such as CMV, EBV, and human herpes virus 6 (HHV-6) reactivate 
and become pathogenic. CMV and EBV are very common viruses and infections are 
wide spread among the population. The danger of a life-threatening CMV re-activation 
has substantially been decreased due to CMV-specific PCR screenings that allow 
(quantitative) detection of the virus already at a subclinical level and the early initiation 
of antiviral treatment. Similarly, screening assays for EBV are routinely applied 
allowing early interventions (by using the anti-CD20 antibody Rituximab), which has 
significantly reduced the rate of a very severe EBV-associated complication, the post-
transplant lympho-proliferative disease (PTLD) [164]. In severe (treatment-resistant) 
cases of CMV and EBV infections approaches of infusing virus specific T-cells are 
currently evaluated. 
In this phase very intensive prophylaxis is undertaken to prevent fungal infections. It 
encompasses prophylactic medication, structural precautions (e.g. disinfection 
routines), and since mold infections are predominantly airborne, isolation rooms and air 
filters. Again, cellular therapies have been also utilized for treating invasive fungal 
infections, namely the transfusion of third-party granulocytes but without striking 
success [165]. 
3.5.3 Graft-versus-host disease  
During the first alloHSCT attempts and especially before the importance of the HLA-
system was recognized, severe adverse immunological events were regularly observed 
and resulted in a deteriorated, life threatening immune reaction. To current 
understanding, this is mostly mediated by alloreactive T-cells of the graft that react 
against the host’s healthy tissues giving rise to the term graft-versus-host disease 
(GVHD). The underlying patho-mechanisms share some common features with the 
beneficial effect of the GVT reaction (Figure 4). The reaction however is amplified to 
such an extent that it affects healthy tissue and becomes harmful, even life threatening 
to the host. GVHD remains the greatest cause of morbidity and mortality after 
alloHSCT and constitutes the biggest hindrance for a successful HSCT.  
It occurs depending on the GVHD prophylaxis, mismatch status and previous therapies 
in 30-60% of all transplanted patients being fatal in about 15% of the cases [119]. The 
most affected organs are the skin, the gut and the liver, but GVHD can theoretically 
involve all areas of the body. Traditionally, GVHD was defined as acute when it 
occurred in the first 100 days after transplantation and chronic GVHD with an onset 
past day 100 after transplantation. In recent years, it has been challenged whether this 
classification still applies and there is a tendency to base the classification on the 
  20 
symptom complex rather than the time-point of onset. Furthermore, a better 
understanding of the different underlying immunological processes that drive acute and 
chronic GVHD respectively gains more significance and recognition.  
 
Figure 4: Graft-versus-tumor (GVT) effect and graft-versus-host disease (GVHD). Both 
reactions are mediated by alloreactive donor T-cells. The GVT effect is strongly desired, since 
it represents the cornerstone for the elimination of residual tumor cells and results in lower 
relapse rates and better overall survival. GVHD on the other hand represents one of biggest 
causes for mortality and morbidity after alloHSCT. Highly activated donor T-cells target 
healthy recipient’s tissue with skin, intestine, and liver being the most affected organs. 
 
The pathophysiology of aGVHD is subject to intense research. Still many mechanisms 
driving aGVHD remain elusive. In the following paragraphs a short outline of todays’ 
understanding of the aGVHD pathophysiology is attempted.  
GVHD seems to constitute a constringent immunological process that spans three 
phases [166]: (Phase 1) the initiation of GVHD starts even before transplantation 
during the conditioning regimen. Radiation as well as chemotherapy damages the host 
tissue encompassing disruptions of protecting mucosal barriers amongst other in the gut 
facilitating the entry of pro-inflammatory microorganisms into the body. The resulting 
inflammation and release of microbial peptides enhances the activation of innate 
immune cells and results in increased secretion of inflammatory cytokines. These 
augmented cytokine levels consequently promote an enhanced recognition of host 
antigens by donor T-cells (Phase two) triggering the activation and proliferation of T-
cells. Finally all these processes disembogue into (Phase 3) effector cell responses that 
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Microbiome is a term 
coined by J. Lederberg “to 
signify the ecological 
community of commensal, 
symbiotic, and pathogenic 
microorganisms that 
literally share our body 
space” [1]. 
damage target organs of GVHD forming a self-amplifying vicious cycle (the GVHD’s 
“perpetuum mobile”). 
GVHD is predominantly a T-cell driven disease [167], but also NK-cells and 
macrophages were identified to be involved [123]. Recent evidence indicates that the 
innate immune system reacting towards microbial peptides holds a pivotal role for 
GVHD pathopysiology [168]. 
Several factors that increase the risk of developing GVHD have been identified: they 
mostly concern matching of recipient and donor (HLA-mismatch, female donors for 
male recipients, preceding alloimmunisation of the donor), age of recipient, 
administered conditioning regimen as well as the type of GVHD prophylaxis [169, 
170]. Recently, more genetic factors have been found to be associated with the onset of 
GVHD. Polymorphisms of cytokine-encoding genes [171], differences regarding the 
pathogen recognition receptors (PPRs) (NOD2/CARD15) [172] and how the body 
copes with antigens of infective organisms seem to have an important impact on the 
development of GVHD.  
A recent study highlighted the importance of the microbiome respectively its regulators 
such as paneth cells in the development of aGVHD. 
Paneth cells reside in the small intestine and regulate the 
microbial flora by secreting anti-microbial peptides such 
as defensins and regenerating islet-derived protein 3 
alpha (Reg3α) [173]. Lower numbers of paneth cells as 
well as lower levels of Reg3α correlate with severity of 
aGVHD and reduced response to GVHD treatment [173, 
174]. The loss of regulation in the gut results in a loss of 
bacterial diversity in favor of increasing prevalence of 
enterococci [175].  
Despite intensive research in terms of developing elegant means for specifically 
targeting established key players of aGVHD, nowadays steroids that act in a rather non-
specific immune suppressive fashion remain the first-line treatment of choice. Taken 
together, most of the approaches for the treatment and prevention of GVHD have 
focused on reducing the alloreactivity of donor T-cells. The most potent effect is 
achieved by depleting donor T-cells from the graft or in vivo.  
Today most commonly the function of donor T-cells is controlled by 
immunosuppressive agents firstly the aforementioned steroids, but also other drugs 
such as calcineurin inhibitors, sirolimus, cyclosporine and methotrexate. Each of them 
is accompanied by characteristic side effects, ranging from increased infection rates, 
mucositis, to even renal or liver failure. Overall, 50-60 % of the afflicted patients will 
respond to an immunosuppressive treatment [92]. 
Cellular therapy for the treatment of aGVHD is a comparatively novel approach and its 
use is discussed in the respective sections for MSCs (see section 2), TRegs (see section 
5) and MDSCs (see section 4).  
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3.6 CONCLUSION 
To date, HSCT transplantation is the most successful immune therapy. It constitutes a 
grand chance for terminally ill persons to be cured and return to an active life. 
However, despite the substantial progress that has been made in the last fifty years, 
many HSCT associated complications remain unresolved and not fully understood. 
Infections, delayed reconstitution, graft rejection and relapse are often life threatening 
and remain together with GVHD the major cause of HSCT related morbidity and 
mortality. Prognosis of high-grade aGVHD is still extremely poor and since the 
response rate to any treatment decreases with advancing degrees of aGVHD, it appears 
obligatory to develop means for preventing or at least alleviating the occurrence of 
severe aGVHD without impairing the GVT effect. The adoptive transfer of MSCs 
seems to constitute an attractive tool to rebalance the immune system. In the following 
two chapters, two more cellular populations are introduced that have been implicated to 
have a beneficial effect on hampering GVHD.  
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4 MYELOID DERIVED SUPPRESSOR CELLS  
4.1 MDSCs IN HEALTH AND DISEASE 
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of 
myeloid cells at different stages of maturation. They encompass myeloid progenitors, 
immature granulocytes, DCs and macrophages. Owing to their heterogeneity, human 
MDSCs cannot be identified by a sole cell-surface-marker guided classification, but 
only in due consideration of their T-cell suppressive function [176, 177].  
MDSCs were first described in the metastatic lymph nodes of head and neck cancer 
patients [178]. Since early studies focused on tumor diseases [179, 180] elevated 
frequencies of MDSC and their immunosuppressive effects have been best 
characterized in malignant diseases of various entities such as hepatocellular 
carcinoma, renal cancer, melanoma, and breast cancer [181-184].  
Increasing evidence suggest that malignant diseases are not a prerequisite for MDSC 
accumulation. Many immunological situations that involve some sort of inflammatory 
response such as autoimmunity [185], sepsis and trauma [186], chronic inflammation 
[187, 188], and also alloHSCT [189-191] can elicit increased frequencies of these 
suppressive cell phenotype. In fact, Hoechst et al. recently identified MDSCs with 
regulatory properties in the peripheral blood of healthy individuals [192] further 
corroborating the notion that MDSCs hold a physiological role in immune homeostasis 
similar to TRegs. In healthy individuals MDSCs constitute only a very low percentage 
(about 0.5%) of the total peripheral blood mononuclear cells (PBMCs) [180, 193] and 
quickly differentiate into mature granulocytes, macrophages and DCs. However, 
immunological conditions as found in cancer and inflammation seem to create an 
environment that leads to the enhanced mobilization and accumulation of these cells.  
 
 
Figure 5: Two-step model of expansion and activation of MDSCs. Cytokines and growth 
factors, which are present in inflammatory processes such as TNF-α, IFN-γ, G-CSF and 
interleukins, mediate the expansion and activation of MDSCs.  
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Accumulation of MDSCs appears to involve two consecutive steps (Figure 5):  
1. Cytokines and growth factors that are abundant during inflammation such as 
TNF-α, G-CSF, GM- or M-CSF [194], IL-6 [195], PGE2 [196, 197], but also 
complement factors (C5a) [198] and cytokine-like pro-inflammatory proteins 
such as S100A8/A9 [199] cause an expansion and mobilization of immature 
myeloid cells [200, 201].  
2. The second signal, which leads to the activation and inception of their 
suppressive function, occurs in the periphery. Myeloid progenitors come in 
contact with inflammatory cytokines such as IL-4, IL-6, IL-13, IFN-γ, and TGF-
β that induce suppressive pathways. These triggering cytokines are secreted by 
activated cells and in the case of malignant disease by tumor (associated) cells. 
Besides activation, this cytokine-“cocktail” also promotes a differentiation arrest 
(by e.g. activation of the transcription factor signal transducer and activator of 
transcription (STAT)3) [200-202]. On the basis of inter-individual biological 
variability respectively the distinct biology of various malignancies, the 
composition of these cytokines differs. This might explain the plethora of 
described (some time inconsistent) MDSC-phenotypes.  
Self-evidently it is extremely difficult to prove this two-signal model of expansion and 
activation in vivo [203]. The pivotal role of the surrounding immunological milieu 
however has been demonstrated indirectly in in vitro studies. Bone marrow derived 
MDSCs exhibit an increased proliferation rate in the presence of activated T-cells, 
which also imped further maturation of MDSCs [204]. Furthermore, 
immunosuppressive MDSCs can be induced from healthy donor derived CD14+ 
monocytes in the presence of tumor cells or by addition of a cocktail including several 
of the aforementioned cytokines and growth factors [195, 196, 200, 201, 205]. Upon 
removal from the tumor milieu, MDSCs can partially differentiate into normal DCs and 
macrophages [206-208] indicating the importance of the extrinsic signals and lack of a 
genetic imprinting.  
Besides the initiation, activation and differentiation arrest of MDSCs, activated T-cells 
seem to represent a checkpoint for their expansion. Similar to T-cell homeostasis in 
which activation always also partially results into an increased cell death (AICD), it 
was shown for murine granulocytic, Fas+ MDSCs that Fas-FasL interaction with 
activated T-cells led to a caspase mediated apoptosis in Fas+MDSC [209].  
Interestingly, MDSCs are not only ‘passively’ expanded in response to their 
environment. MDSCs themselves might actively promote their own accumulation 
within an autocrine feedback loop, as paradigmatically shown for MDSCs isolated 
from ovarian and prostate cancer patients. These cells secrete IL-10, which amongst 
other effects, causes the sequestration of HLA-DR and consequently leads to higher 
frequency of HLA-DRlow/neg monocytic MDSCs [210].  
4.2 PHENOTYPE 
In the mouse MDSCs are defined by the expression of the myeloid lineage 
differentiation antigens Gr-1 and CD11b [211]. Based on the level of Gr-1 expression, 
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MDSCs are subdivided in a CD11b+Gr1high (CD11b+Ly-6G+ Ly-6Clow) expressing 
granulocytic and a CD11b+Gr1low (CD11b+Ly-6ChighLy-6G-) monocytic MDSC subset 
[212]. In contrast to murine MDSCs their human counterparts lack specific markers and 
are therefore much harder to define phenotype wise [187]. As yet, a steadily growing 
number of phenotypes have been described in various pathological conditions [213]. 
Consensus is that human MDSCs are displaying a lack or at least significantly 
decreased levels of markers characteristic for mature myeloid cells [214]. Furthermore, 
they regularly have a pronounced expression of CD11b an integrin required for 
monocytes and neutrophils to interact with the endothelium, the transmembrane 
receptor CD33 and display - in a non-typical fashion for myeloid cells - an absence or a 
very low expression of HLA-DR [193, 215].  
 
 
 
 
 
 
Figure 6: Gating strategy to identify CD14+HLA-DRlow/neg MDSCs. This FACS blot 
exemplifies how frequencies of MDSCs can vary between a healthy donor (HD) and a person 
that experiences some kind of inflammatory reaction in this case alloHSCT (Pat) [190]. 
In recent attempts to categorize human MDSCs, the cells have been grouped based on 
the expression of the LPS co-receptor CD14, into monocytic (CD14+HLA-
DRlow/negCD33+) [216-218] and granulocytic MDSCs (lineage negative (CD3, CD14, 
CD19, CD56)) CD33+ HLA-DRlow/neg [176, 177]. These two subpopulations can occur 
exclusively but overlaps have also been reported [219, 220]. Multiple phenotypes have 
been described in different diseases [221] indicating that the population of MDSCs is 
shaped by their surrounding micro milieu as afore described in more detail. 
 
Marker Function Reference 
CD80, CD83, DC sign Co-stimulatory molecules [183, 222] 
IL-4 receptor α (CD124) Activation and suppression [223-225] 
M-CSFR (CD115) Growth factor receptor [224, 226] 
TNFRII MDSC accumulation, apoptosis inhibition [203, 227] 
VEGFR1  [177, 228]  
CD15, CD66b  Granulocytic marker [177, 229, 230] 
CD62L Adhesion molecule [177, 190, 231] 
CD49d Integrin  [232] 
CD16 Fc receptor [177] 
CCR2 (CD192) Chemokine receptor [227] 
Table 4: Phenotypic markers that have been described for human MDSCs. 
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4.3 T-CELL SUPPRESSIVE ACTIVITY 
MDSCs exhibit a plethora of direct and indirect mechanisms to suppress T-cell 
activation and proliferation [233, 234] (Figure 7). This diversity seems to be partially 
attributed to their monocytic or granulocytic nature, maturation and activation status 
and is consequently shaped by their surrounding microenvironment similar to their 
phenotype. Most likely, MDSCs constitutively exhibit more than one suppressive 
pathway, however since most investigators concentrated on the most distinguished, 
protruding suppressive mechanism the co-existence of several suppressive mechanisms 
has only been evaluated in few studies [183, 235]. 
The basic question regarding an antigen-specific MDSC-mediated suppression has not 
been completely resolved. Interestingly, MDSCs are able to take up and process soluble 
antigens and to subsequently present them to T-cells [231, 236]. Since antigen-
presentation by MDSCs is - unlike in professional APCs inadequate (e.g. lack of co-
stimulation) - it is speculated whether it represents a very elegant method for inducing 
tolerant CD4+ and CD8+ T-cells in an antigen-specific manner [204].  
 
 
Figure 7: Immune suppression exerted by MDSCs. MDSCs release a plethora of immune 
regulatory factors such as IL-10, TGF-β and express enzymes such as inducible nitric oxide 
synthetase (iNOS) and Arginase-1 (ARG1) that deplete arginine an essential amino acid for T-
cell activation from the environment. MDSCs produce furthermore reactive oxygen species 
(ROS) via NADPH oxidase (NOX2) that react with nitric oxide (NO), which is released by the 
metabolization of L-arginine by iNOS. This forms the radical peroxynitirite (ONOO-). 
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4.3.1 Lymphocyte nutrient depletion  
One of the first identified mechanisms of MDSC-mediated suppression involved the 
metabolism of the essential amino acid arginine. L-Arginine is utilized for protein 
synthesis and plays a decisive role for T-cell activation (TCR-signaling) and 
proliferation.  
In MDSCs two enzymes have been identified that lead to arginine depletion: arginase 1 
(ARG1) [237] and inducible nitric oxide synthetase (iNOS). First, cells take up arginine 
by the cationic membrane transporters (CATs). Next, ARG1 metabolizes arginine into 
ornithine and urea thereby depleting it from the environment and additionally 
generating immune regulatory metabolites (e.g. putrescine, L-proline) [215, 238]. Up-
taken arginine is converted by iNOS [200] into citrullin while nitric oxide (NO) is 
released. Interestingly, the expression of these two enzymes seems to be competitively 
regulated [239] and they are normally not 
simultaneously active in the same cell. Furthermore, 
in some cell populations (e.g. macrophages) 
expression of ARG1 and iNOS seem to be linked to 
maturation [240, 241].  
MDSC-mediated arginine deficiency impairs the 
proliferation and IFN-γ production of T-cells [181, 
183] and leads to a decreased CD3ζ-chain expression. 
CD3ζ-chain is decisive for T-cell signaling and its 
decreased expression results in impaired T-cell signal 
transduction [242]. In a murine GVHD model, ARG1 
activity of MDSCs could significantly inhibit T-cell 
activation, proliferation and inflammatory cytokine 
release [189]. One underlying mechanism of the 
observed effects of L-arginine starvation on T-cells 
could be an impaired up-regulation of cell cycle 
regulators cyclin D3 and cyklin dependent kinase 4 
(cdk4) which results in a cell cycle arrest in the G0-
G1 phase [238]. ARG1 mediated effects could be 
abolished in vitro by the exogenous L-arginine 
addition or inhibition of ARG1 with nor-NOHA (Nωr-hydroxy-nor-arginine) and L-
NMMA (L-NG-monomethyl arginine acetate) [183, 243].  
Nitric oxide (NO) release leads to the impaired activation and function of T-cells. It 
inhibits for example Janus kinase (JAK) 3 and STAT5 signaling [244] and suppresses 
the expression of HLA-DR [245]. It also has been associated with the induction of T-
cell apoptosis [246]. Furthermore, in the presence of reactive oxygen species (ROS), 
NO is converted to peroxynitirite (ONOO-). Peroxynitirite is a radical that randomly 
interacts with proteins causing nitration. In a mouse model, it was demonstrated that 
this nitrotyrosine accumulation also occurs in the TCR-region. It impairs HLA-class 
mediated antigen recognition resulting in an impaired T-cell response [236]. 
ARG-1 and iNOS expression seems to be impacted by the surrounding environment. 
Inflammation accompanied by the secretion of cytokines such as IFN-γ, IL-4 and IL-13 
by activated effector cells might be involved in the up-regulation of ARG-1 activity 
respectively the induction of iNOS [189, 247]. IFN-γ is known for its activating impact 
CD3ζ-chain (CD247) is a key 
component for signal 
transduction of the TCR. It 
contains three immunoreceptor 
tyrosin-based activation motifs 
that transduce activation upon 
antigen recognition to 
intracellular signaling. Low 
expression of CD3ζ-chain 
results in impaired T cell 
activation. 
A cell cycle or cell division 
cycle encompasses sequential 
events involved in cell division: 
(1) quiescent G0-Phase,  
(2) Interphase, (‘preparatory 
phase’) encompassing G1-Phase, 
S-Phase, G2 Phase and the cell 
division itself (3) mitosis 
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on the transcription factor STAT1, which is responsible for the up-regulation of iNOS 
and ARG1 in MDSCs. Furthermore the link of IFN-γ and STAT1 could be one reason 
that strongly activated T-cells are more easily suppressed by MDSC [204] and blocking 
of IFN-γ abolishes the suppressive capacity of MDSCs [231, 248]. Up-regulation of 
iNOS/ARG1 has also been associated with STAT6 activation increasing the 
suppressive function of MDSC [247] (Figure 8). 
 
 
Figure 8: STAT signaling pathways involved in the expansion and activation of MDSCs. 
Cytokines and growth factors that are released in inflammation and malignant diseases such as 
IL-6, IL-4, G-CSF and VEGF activate the family of STAT transcription factors. STAT3 plays a 
central role for a differentiation arrest, which together with an enhanced myelopoiesis leads to 
MDSC accumulation. STAT1, STAT3, and STAT6 activation promote the up-regulation of 
immunosuppressive enzymes such as iNOS, ARG1, and COX-2 as well as to the increased 
production of suppressive cytokines such as TGF-β and MDSC-inducing factors such as IL-6, 
IL-10 and G-CSF. Increased ROS production, which has been shown to favor myeloid 
differentiation arrest and T cell suppression, is observed upon STAT1, STAT3 and STAT6 
activation. 
 
4.3.2 Oxidative stress 
Reactive oxygen species (ROS) such as 
hydrogen peroxides or superoxide anions are 
main by-products of the cellular respiration (in 
the mitochondria) and furthermore produced 
by the membrane bound enzyme complexes of 
nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases (Figure 9). ROS is a 
double-edged sword in immunology [249]: 
Reactive Oxygen Species (ROS) 
encompass superoxide (O2-), 
hydrogen peroxide (H2O2), hydroxyl 
radicals (OH-), and instable products 
that result from lipid peroxidation. 
ROS readily damage intracellular 
targets such as DNA, carbohydrates 
and proteins and has to be balanced 
by the cellular anti-oxidants.  
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ROS play a central role in cell signaling as an important second messenger and also 
possess a direct role in immune function, in particular in the elimination of pathogen by 
phagocytes via the so-called oxygen burst. However, a constant, increased production 
of ROS, which outweighs the cellular anti-oxidative capacity epitomized by the thiol-
containing molecules glutathione, and several ROS-metabolizing enzymes such as 
catalase or superoxide dismutase, results in oxidative stress. Oxidative stress causes 
inter alia potent immunosuppression and constitutes one of the known tumor escape 
mechanisms. It inhibits the recruitment of CTLs [250] and suppresses T-cell function 
[251]. Interestingly, immune suppressive TRegs exhibit an enhanced resistance to 
oxidative stress [235].  
 
Figure 9: Composition of nicotinamide adenine dinclueotide (NADPH) oxidase. NADPH 
oxidase is a transmembrane enzyme complex that produces superoxide anions upon activation. 
It consists of six subunits: Rho related C3 (Rac) and five phagocytic oxidase (phox) units: gp91, 
p22, p47, p40 and p67. NADPH oxidase plays a pivotal, physiological role in microbial defense 
by neutrophils. In various malignant and inflammatory diseases, an immoderate activity of 
NADPH oxidase is observed in various cell types and tissues. This results in an excessive 
production of superoxide leading to oxidative damage of DNA, proteins, and lipids and 
immune alterations 
 
MDSCs, especially the granulocytic subsets have been shown to regularly exhibit an 
increased production of ROS [211, 229]. MDSCs produce ROS mainly via the NADPH 
oxidase [252] und an up-regulation of its subunits gp91 und p47 was observed for 
MDSCs in patients with advanced melanoma [183]. ROS serves several functions for 
MDSCs: (1) suppression of the immune system as demonstrated for antigen specific 
CD8+ T-cells [211, 252], and induction of apoptosis in activated T-cells by decreasing 
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Bcl-2 expression [253]. In fact, antagonizing ROS by using for example the ROS 
metabolizing enzyme catalase can revert MDSC-mediated suppression by increasing 
IFN-γ production of T-cells in presence of MDSCs [211, 220]. The second function 
ROS holds is the (2) promotion of MDSC expansion: ROS abets the phosphorylation of 
the transcription factor STAT3. STAT3 plays a pivotal role for several aspects in 
MDSC immunology. It controls the suppressive activity of MDSCs as well as the 
myelopoiesis and blocks their further differentiation into granulocytes, macrophages 
and DCs [183, 200, 252] (Figure 8).  
Inflammatory cytokines such as IL-3, IL-6, IL-10, GM-CSF [254], but also cytokines 
secreted by MDSCs themselves as TGF-β promote ROS production within an 
(autokrine) feedback loop [183].  
4.3.3 Alternative suppressive mechanisms 
The suppressive activity of MDSC has been associated with the production of various 
immune regulatory cytokines such as IL-10 [197], TGF-β [255, 256] and PGE2 [257]. 
These cytokines play a role in direct immunosuppression and have been associated with 
the MDSC driven tumor promotion [255, 258, 259], and induction of TRegs (see 
following section). 
Recently, CD14+HLA-DRlow/neg MDSCs have been identified in breast cancer [184], 
but also in GHVD which exhibited an increased expression of IDO [190]. IDO is an 
enzyme, which metabolizes tryptophan an essential amino acid to kynurenine-pathway 
metabolites. Low tryptophan levels leads amongst other to the inhibition of the mTOR 
kinase pathway. Furthermore, the resulting kynurenine metabolites namely, 3-
hydroxyanthranilic acid and quinolinic acid, hold immune regulatory properties [260]. 
IDO plays an important role for acquired peripheral tolerance and the control of severe 
inflammation [261]. One characteristic is its quick upregulation respectively 
inducement upon inflammatory stimuli such as IFN-γ [262]. 
4.3.4 T-cell differentiation and trafficking 
MDSCs do not only directly suppress T-cell responses but also amplify their 
immunosuppressive capacity by the TRegs induction [225, 263] and expansion of 
antigen-specific nTRegs. The exact mechanisms have not been elucidated but production 
of cytokines such as IFN-γ, TGF-β and IL-10 [225, 263] as well as direct cell-cell 
interactions via CTLA4 [222] and CD40-CD40L interactions [264] seem to play a role. 
TRegs play an important role in regulating the immune responses and their expansion in 
cancer constitutes one of the well-established immune escape mechanisms [265]. This 
TRegs inducing function is albeit not limited to MDSCs in cancers [181, 225, 263], but 
also utilized by immature myeloid cells in healthy persons to orchestrate the immune 
system: It was shown that CD14+HLA-DR- cells induce in CD4+ T-cells the production 
of IL-10 and convert conventional T-cells into FoxP3+T-cells while promoting the 
transdifferentiation of Th17-cells into iTReg [192].  
Furthermore, MDSCs confine the trafficking of T-cells to secondary lymphoid organs, 
which is a key step for the T-cell priming. Expression of CD62L (L-Selectin) allows 
cells to enter secondary lymphoid organs. MDSCs have been shown to decrease the 
CD62L expression on naïve T-cells by tumor necrosis factor-α-converting enzyme 
(TACE) thereby hampering their priming in secondary lymphoid organs [266] 
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4.4 CONCLUSION 
MDSCs have emerged as an important immune regulatory population that exists 
physiologically at low frequencies. In situations of immune activation such as 
inflammation, cancer or within the framework of an emergency myelopoiesis MDSCs 
can accumulate. Due to the plethora of identified phenotypes in human diseases, a sole 
phenotypic identification does not suffice to reliably identify these cells. To 
experimentally prove their immunosuppressive function towards T-cells is pivotal for 
naming them MDSCs.  
Taken together, similar to TRegs, described in the next chapter, MDSCs might be - 
according to the given condition - a friend (trying to control acute inflammation) or a 
foe (suppressing immune responses against cancer cells). In the future, it will be of 
great interest to further delineate the underlying mechanisms responsible for their 
expansion and activation as well as their immune suppressive strategies. These insights 
could provide the sound basis for developing strategies to target specifically MDSCs or 
to exploit their therapeutic potential (e.g. in GVHD). 
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5 REGULATORY T-CELLS  
The maintenance of self-tolerance and immune regulation is largely attributed to a 
suppressive subpopulation of T-cells. The existence of so-called suppressor T-cells was 
first described by Gershon et al. in 1970 [267]. It took however another 25 years until 
Sakaguchi et al. could identify a specialized subset of CD4+CD25+ T-cells that could 
prevent autoimmune disease in a murine model [268]. Based on their immune 
regulatory function in maintaining tolerance to auto- and alloantigens, these cells were 
named regulatory T-cells (TRegs) [269].  
TRegs are primarily classified according to their origin (Figure 10): TRegs that derive 
from the thymus are named natural occurring TRegs (nTRegs) and TRegs that are induced 
from activated conventional T-cells (TConv) in the periphery are called induced TRegs 
(iTRegs). The exact mechanisms how iTRegs are induced from TConv have not yet been 
deciphered, but two pivotal aspects have been ascertained to promote their generation: 
(1) inadequate antigen presentation (2) and the presence of high levels of cytokines 
such as IL-2, IL-10, and TGF-β [265]. Several studies have reported that TReg-induction 
can also be cell-mediated. Immunosuppressive cell populations such as MSCs [31, 48] 
(see section Chapter 2), MDSCs [192] (see Chapter 4) and even nTRegs [270] appear to 
amplify their own suppressive capacity (in terms of cell numbers but also duration of 
suppressive activity) by inducing additional regulatory phenotypes.  
 
 
Figure 10: Origin of regulatory T cells (TRegs). Natural occurring TRegs develop in the thymus 
from T cell progenitors (thymocytes). Furthermore, TRegs can be induced from mature 
conventional T cells in the periphery as here depicted for CD4+ T cells, which can be induced to 
become e.g. IL-10+ Tr1 cells or TGF-β+  Th3 cells. Several suppressive cells such as MSC and 
MDSC as well as the presence of high levels of cytokines namely IL-2, TGF-β and IL-10 in 
combination with inadequate antigen stimulation mediate this process.  
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5.1 PHENOTYPES  
One of the first phenotypic markers for defining nTRegs was the high expression of 
CD25, which is the alpha-chain of the high-affinity receptor for IL-2 [271]. IL-2 is 
secreted by stimulated T-cells [272] and drives their proliferation and clonal expansion 
[273]. Although nTRegs themselves are normally anergic and do not produce IL-2 upon 
stimulation, IL-2 plays an essential role for TRegs function, proliferation and survival. 
IL-2 seems to reconstitute a feedback circuit: activation of T-cells simultaneously 
promotes the existence of TRegs and furthers their immunosuppressive function [274]. 
Furthermore, the high consumption of IL-2 by TRegs, results in shortage of IL-2 for 
naïve and effector T-cells leading to their apoptosis [275]. This has been proposed to 
represent an immunosuppressive feature of TRegs. 
Since CD25 expression can also be increased on activated TConv cells, CD127 (IL-7Rα 
chain) was added to the panels for identifying nTRegs. It has been shown that nTRegs 
(unlike activated T-cells) express CD127, if at all only at low levels [276], which in 
addition correlates inversely with the expression levels of the transcription factor FoxP3 
[277]. FoxP3 has been identified as the prototypic master regulator for nTRegs and 
represents one of the most reliable (intracellular) phenotypic markers of nTRegs [278]. 
nTRegs depend on a high and continuous expression of FoxP3 for their development and 
suppressive function [279]. The key function of FoxP3 and nTRegs for immune 
homeostasis can be observed in the so-called IPEX syndrome (immunodysregulation 
polyendocrinopathy enteropathy X-linked syndrome), which is associated with heavy 
autoimmunity and is frequently lethal in the first years of life [280]. The human IPEX 
locus was identified as Xp11.3-Xq13.3 [281] and IPEX mutations may lead to 
alterations in the forkhead motif in the FOXP3 coding region. Recent studies 
emphasize the role of the methylation status of the FOXP3 promoter region [282]. This 
data suggests that methylation analyses could represent an even more accurate method 
(than FACS) for identifying and even quantifying “pure” nTRegs. But obviously more 
research and development is required for introducing such method into the clinical or 
laboratory routine. 
 
 
 
Figure 11: Phenotypical characterization of naturally occurring TRegs. This figure shows a 
representative example for the FACS Blot gating strategy for nTRegs. Gating on CD3+CD4+ T-
cells is followed by the identification of the CD25hiCD127low/neg subpopulation, which expresses 
the transcription factor FOXP3 (depicted as histogram, grey = isotype control) [51]. 
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The afore described phenotypic markers are characteristic for nTRegs and do not 
necessarily apply for iTRegs (Table 5), which sometimes express only low levels 
respectively no FOXP3 and CD25 [265, 283]. The two most frequently described 
subsets of iTRegs are mostly defined by their high expression of the immune modulating 
cytokines IL-10 (IL-10+ TReg1 cells (Tr1 cells)) and TGF-β (TGF-β+ T helper (Th) 3) 
[265] upon antigen-stimulation. 
 
Table 5: Regulatory T-cell subsets and suppressive mechanisms. Different regulatory T-
cells subsets have been identified which differ in phenotype as well as their mode of 
immunosuppression. Adapted from [265]. 
 
5.2 SUPPRESSIVE MECHANISMS 
TRegs suppress as demonstrated in numerous in vitro and in vivo studies the activation 
and expansion of cells from the innate and adaptive immune system, thereby impacting 
cellular and humoral immune responses. Several prerequisites have to be met for TRegs 
mediated suppression as (1) physical proximity to target cells, (2) sufficient number of 
TRegs and (3) preceding activation of TRegs by TCR-ligation [284-286]. TRegs activation is 
antigen specific, however once they are activated their suppression is antigen 
independent (“bystander suppression”) [285]. Interestingly, in order to prevent 
autoimmune disease and maintain immunological self-tolerance, TRegs might even be 
“auto-reactive” in terms of (self-) antigen specificity, which warrants a continuous 
stimulation by self-antigens [284].  
Several soluble factors such as immune regulatory cytokines most notably IL-10 and 
TGF-β are released by activated TRegs. Both cytokines seem to play a pivotal role in 
Cell Type Origin Phenotype 
Suppressive 
mechanisms 
nTRegs Thymus   
 CD4 nTRegs  CD4+CD25+FOXP3+CD127-/low CTLA4+ 
LAG-3+GITR+ 
contact, 
cytotoxicity, 
IL-10, TGF-β 
 CD8 nTRegs  CD8+CD25+FOXP3+CTLA4+CD122+ contact 
Adaptive/ 
Induced TRegs 
Periphery 
  
 CD4 nTRegs like  CD4+CD25+FOXP3+CTLA4+GITR+ contact (requires 
IL-2 and TGF-β) 
 Tr1  CD4+CD25+FOXP3+ IL-10 
 Th3  CD4+CD25+FOXP3+ TGF-β, IL-10 (to a 
lesser extent) 
 CD8 iTRegs  CD8+CD25+FOXP3+ IL-10, TGF-β 
 CD8 iTRegs  CD8+CD25+CD28+FOXP3+CTLA4+ GITR+ contact, IL-10, 
ILT3, ILT4 
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TRegs mediated suppression in vivo, as it has been e.g. shown for IL-10 in a murine 
model for autoimmune diseases [287, 288]. In most in vitro models, secretion of TGF-β 
and not IL-10 was observed in most nTRegs-cultures [289]. The existence of TGF-β+ 
Th3 cells were first mentioned in association with the inhibition of Th1-cells via 
secretion of TGF-β in a murine MS model [290] with their importance being 
recognized in several autoimmune disease models in the following years [291].  
Besides direct suppression, TGF-β and IL-10 foster the induction of additional immune 
regulatory cells such as IL-10+ Tr1 cells and TGF-β+ Th3 cells from naïve T-cells at the 
site of action [265, 270]. Present data indicates that these iTRegs play a physiological 
role in the maintenance of tolerance in the gut environment and inflammatory 
responses. A similar effect as IL-10 and TGF- β, has PGE2, which is generated by 
COX-2 and mainly released by iTRegs: it leads to the induction of an immune regulatory 
phenotype in CD4+ T-cells [292] and furthermore suppresses effector T-cells [293].  
 
 
Figure 12: Suppressive mechanisms identified for regulatory T cells (TRegs). TRegs secrete 
suppressive cytokines such as IL-10, PGE2 and TGF-β, which directly suppress effector T-cells 
(Teff), but also further promote induction of iTRegs. CTLA4 expressed on the TReg-surface 
directly inhibits DCs. Furthermore TRegs express high levels of CD25 that is part of a high 
affinity receptor for IL-2 (IL-2R). Thereby they can outcompete activated T-cells in terms of 
IL-2 uptake leading to the anergy of the activated T-cells and cell death. TRegs can also directly 
kill conventional T-cells by injecting toxic levels of cyclic adenosine monophosphate (cAMP) 
via membrane gap junctions or in a granzyme B/perforin dependent way. TRegs furthermore 
deplete the environment of adenosine triphosphate (ATP) by metabolizing it into adenosine a 
potential suppressant of T-cells by ectoenzymes (CD39 and CD73). 
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Furthermore, the elevated levels of all these cytokines lead to a suppressive, tolerogenic 
milieu by reducing the capacity of APCs to induce alloantigen-specific T-cells [289, 
290]. These suppressive effects can also be observed in the tumor microenvironment, 
which in this case hinders anti-tumor immune responses [265]. Recently, IL-35, which 
belongs to the IL-12 heterodimeric family was identified as an essential player for the 
full suppressivity of TRegs [294]; however so far its role has been mostly identified in 
the murine system, while its impact on the suppressive capacity of human TRegs as well 
as its effect on other cells than T-cells has not been elucidated.  
The role of IL-2 consumption by high affinity receptor CD25 leading to IL-2 starvation 
as a mean of TReg mediated suppression has been subject of debate. A recent study has 
shown that IL-2 deprivation leads to apoptosis [275], however IL-2 depletion does not 
seem to be the premise for effector T-cell suppression [295].  
TRegs express several inhibitory receptors such as fibrinogen-like protein 2 (FGL2), 
cytotoxic T-lymphocyte antigen 4 (CTLA4) and lymphocyte-activation gene 3 (LAG-
3). CTLA4 and LAG-3 are constitutively expressed on nTRegs. They have direct 
inhibitory effects on T-cells and also indirect T cell regulating effects by modulating 
APC function: CTLA4 is a ligand for accessory molecules (such as CD80/CD86) 
expressed on activated T-cells and its binding to the T-cell transmits an inhibitory 
signal. Furthermore, CTLA4 binding to CD80/CD86 on DCs seems to lead to their 
down-regulation of these co-stimulatory molecules in a negative feedback manner. This 
leads to a decreased T-cell stimulation. TRegs furthermore impair DC maturation by e.g. 
binding of LAG-3 to HLA-Class II molecules, which are expressed on several types of 
APCs. This LAG-3 binding induces a negative signal for the maturation of APCs [265]. 
CTLA4 on the other hand can amplify its suppressive effects on T-cell activation and 
function by the induction of IDO in APCs [296]. IDO metabolizes tryptophan into 
kynurenine and several immune regulatory metabolites. FGL2 has been shown to 
induce B-cell apoptosis thereby decimating their interaction with activated T-cells [297, 
298].  
Cyclic adenosine monophosphate (cAMP) is an important second messenger for cell 
signaling. TRegs utilize cAMP injections via membrane gap junctions into target cells to 
impair T-cell proliferation and IL-2 production [299]. TRegs can also alter the levels of 
cAMP by influencing the extracellular nucleotide/nucleoside levels of for example 
adenosine by CD39 (ecto-nucleoside triphosphate diphosphohydrolase) and CD73 
(ecto-5’-nucleotidase) [300] expressed on their cell membrane. Adenosine inhibits 
function of T-cells through the adenosine receptor 2A [301]. Furthermore, it has been 
shown that TRegs also utilize ROS produced by NADPH oxidase in conjunction with 
TGF-β to suppress CD4+ effector cells [302].  
Direct cytolysis of effector cells mediated by TRegs is accomplished by the perforin-
granzyme pathway or by the induction of apoptosis by TRAIL-DR5 pathway [301]. 
Granzymes are serine proteases that utilize perforin to enter target cells, where they 
induce apoptosis by cleaving important substrates. Several studies have shown that 
TRegs induce cytolysis in monocytes T-, B- and NK-cells as well as CTLs in a granzyme 
B dependent manner [265, 301, 303, 304]. However, if the induction of apoptosis is a 
pivotal suppressive mechanism in vivo, has yet to be clarified.  
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5.3 THERAPEUTIC POTENTIAL FOR TREGS IN THE TREATMENT OF 
GVHD 
The adoptive transfer of TRegs has gained momentum as a mean to treat GVHD 
following the seminal studies carried out by Edinger et al. In murine mismatched 
alloHSCT models, it has been shown that the ratio of TRegs to CD4+ Tconv-cells strongly 
determines the outcome of GVHD [305, 306]. Furthermore, it has been shown that this 
ratio (TRegs to CD4+ Tconv-cells) plays an important predictive role for long-term graft 
tolerance in alloHSCT and also liver and kidney transplantations [307]. Many immune 
monitoring ex vivo studies concluded that humans that have lower frequencies of TRegs 
in the peripheral blood after HSCT hold a higher risk of developing GVHD [308, 309]. 
This was not only the case for diminished thymic derived nTRegs but also IL-10+ Tr1 
TRegs [310], which has been associated with increased intestinal inflammation [289]. 
In animal models it has been shown that TRegs suppress hyperactive, autoreactive T-
cells (GVHD) while maintaining the GVT effect [311, 312] and without impairing 
antiviral T-cell immunity [313].  
One important prerequisite for a successful adoptive cellular therapy is to gain 
sufficient numbers of the transferred cells. Different approaches have been undertaken 
ranging from in vitro expansion of cord blood units [314], to ex vivo isolation of 
CD4+CD25+ TRegs [315, 316]. The first clinical studies showed a beneficial effect 
without an increased relapse or higher infection rate [314-316]. Another issue that has 
to be resolved which is the best time point, the optimal cell dose for transfusion and 
what phenotype of TRegs is associated with the highest suppressive capacity and should 
therefore be preferentially selected. CD4+CD25high TRegs that also express CD45RA, 
inducible T-cell costimulator (ICOS) and are negative for CD127 seem to be most 
suitable [317]. Infusion numbers range from 100,000 to 1,000,000 TRegs per kg body 
weight [314, 316, 318]. Interestingly, it seems to depend on the utilized expansion 
protocol, if these numbers are sufficient and effective.  
Recently, it was shown that in patients with chronic GVHD low dose treatment with 
IL-2 (0.3×106, to 1×106 international units (IU) per square meter of body-surface area) 
leads to in vivo expansion of TRegs [319]. It is thought that this low dose of IL-2 
stimulates specifically TRegs due to their higher affinity for IL-2 as compared to 
conventional T-cells. The clinical effects were promising and therefore further studies 
have to show whether the in vivo induction of TRegs could represent a (more convenient) 
Treg-based approach than ex vivo expansion with following adoptive cell transfer. 
5.4 CONCLUSION 
Regulatory T-cells (TRegs) represent a pivotal checkpoint for the immune system 
preventing auto-immunity and chronic inflammation. In addition to the well-established 
thymus-derived naturally occurring nTRegs, TRegs can be induced from regular TConv cells 
by a number of cytokines (e.g. IL-10) and other cell types (e.g. MDSCs). This so-called 
“on-site“generation is an elegant mean for a timely and most likely locally restricted 
reaction against inflammatory processes.  
TRegs exhibit a plethora of immune regulating functions that have been mostly studied 
in terms of their impact on T-cell-responses. However, most components of the innate 
and adaptive immunity appear to be affected directly or indirectly by TRegs. Taken 
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together, TRegs keep the immune system in balance. Consequently, reduced or deficient 
TRegs are associated with autoimmunity and an increased risk for developing aGVHD 
after alloHSCT. During the last five years, adoptive TReg transfer and (pharmacological) 
means (e.g. low-dose IL-2) for promoting an in vivo TRegs expansion have both been 
heavily investigated and emerging as a promising option for treating GVHD. However, 
it is important to note that increased TReg frequencies are not per se beneficial. In 
malignancies the immune suppressive effect of TRegs is regularly “hijacked” by tumor 
cells, which should be always carefully considered in patients transplanted for 
underlying neoplasias. Compelling evidence suggests that TReg accumulation plays a 
key role for the tumor immune escape – one of the hallmarks of cancer.  
Taken together, TRegs are a double-edged sword that can be “boon and bane” to the host 
depending on the immunological situation and underlying disease(s). 
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6 AIMS 
 
The aim of this thesis was to further decipher the impact of MSCs on the immune 
system. The following questions were addressed: 
 
1. MSCs are often transfused into inflammatory environments; a potent 
protection from oxidative stress is necessary to maintain their immune 
regulatory function. HO-1 is a potent anti-oxidative, immune regulatory and 
cytoprotective molecule that, as previously shown, furthermore exerts a T-cell 
suppressive effect in rat MSCs [320]. The questions addressed in the first 
study were therefore: does HO-1 serve a dual role in human MSCs as an 
antioxidant with immune regulating functions?  How is its expression and 
function impacted by inflammatory licensing? 
 
2. HLH is a highly inflammatory disease of often-fatal outcome. The only 
curative regimen for this disease is allogeneic HSCT. There are cases in which 
a suitable transplant is not available or the health condition of the patient does 
not allow the induction of the therapy. Could MSCs therefore constitute a 
mean to bridge the therapeutic gap and furthermore limit the disease-
associated hyper-inflammation until allogeneic HSCT is feasible? Does MSC 
treatment lead to a measurable immunological impact? 
 
3. MSCs have been applied in studies to treat complications after alloHSCT and 
aGVHD. Do MSCs transfused in patients lead to measurable immunological 
alterations compared to placebo controls and for how long are these 
alterations present? 
 
4. Recently, it was shown for animal models that regulation of inflammation by 
MSCs has been associated with the induction of immune suppressive myeloid 
cells [22]. Do infused MSCs lead to the induction of a regulatory phenotype in 
myeloid cells in patients after with aGVHD after aHSCT and do these 
myeloid cells hold a suppressive capacity that potentially limits GVHD? 
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7 MATERIAL AND METHODS 
 
All information regarding material and applied methods is detailed in the respective 
papers (I-IV). This section addresses some general aspects.  
7.1 PATIENTS AND DONORS 
The studies included in this thesis were all approved by the ethics committees of the 
Karolinska University Hospital (Stockholm, Sweden) and the University Hospital of 
Erlangen (Erlangen, Germany) respectively. Healthy donors and patients respectively 
their parents signed an informed consent in accordance to the Declaration of Helsinki.  
Patients were enrolled from the Hematology Center at the Karolinska University 
Hospital in Huddinge and the Department of Hematology and Oncology at the 
University Hospital of Erlangen, Germany. The patients undergoing alloHSCT were 
treated with standardized protocols following international guidelines and 
recommendations.  
In the presented studies, adoptive MSC transfer was utilized for steroid refractory acute 
GVHD and HSCT related complications [51] and the treatment of HLH [85]. Steroid 
refractoriness in GVHD patients was diagnosed, if steroid treatment (≥ 2 mg per kg per 
day) led (A) to no clinical improvement after at least seven days, or (B) in the case of 
GVHD progression by at least one grade, within 72h. 
7.1.1 Patient material 
Peripheral blood mononuclear cells (PBMCs) were retrieved by density gradient-based 
centrifugation and stored in 10% dimethyl sulfoxide (DMSO) in liquid nitrogen until 
further use. For subsequent isolations of specific cell subsets such as monocytes or T-
cells magnetic bead–based methods (Miltenyi Biotec, Bergisch Gladbach, Germany) 
were applied.  
Serum was immediately processed and stored at -80°C until analysis. 
MSCs were isolated from the bone marrow of unrelated unmatched donors harvested 
from the iliac crest as described previously in detail [94, 321]. In short, heparinized 
bone marrow was separated according to the density gradient and the bone marrow 
mononuclear cells were plated in DMEM with 10% FCS. The culture procedure was in 
line with the recommendations of the MSC consortium (EBMT) and the Swedish 
Medical Products Agency. The purified and expanded MSCs fulfilled the ISCT criteria: 
they expressed CD73, CD90 and CD105 and were negative for CD3, CD14, CD31, 
CD34, CD45, and HLA-DR. They differentiated into cartilage, bone and fat 
(multipotency) using special culture conditions and inhibited mixed lymphocyte 
cultures in vitro (immune regulation). All cells for clinical and research purposes were 
cultured according to well-established protocols for three passages [322] and 
subsequently cryopreserved in 10% DMSO until infusion or further utilization. Release 
criteria for MSCs included viability of >95%, absence of visible clumps, and sterility. 
In average two million cells per kg bodyweight (range: 1.5 – 2.2) diluted in saline 
solution supplemented with 10% AB plasma were infused for 15 – 20 minutes. 
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7.2 METHODS 
7.2.1 T-cell suppression assays (Paper I and III) 
Mixed lymphocyte reactions (MLRs) or bead-triggered (i.e. anti-CD3- and anti-CD28 
activating beads) T-cell stimulation have been established to mimic T-cell responses in 
vitro and can be used for evaluating the suppressive activity of regulatory cells such as 
MSCs. Briefly, the impact of immunosuppressive cells on classical lymphocyte 
responses to activation such as proliferation (primarily) or cytokine production are 
assessed. 
In this thesis two common experimental set-ups were utilized: (1) for assessing the 
suppressive capacity of MSCs [31], pooled irradiated (for preventing proliferation) 
allogeneic peripheral blood lymphocytes (PBLs) from five healthy donors were used as 
stimulators of non-irradiated PBLs from another donor (responder cells) and co-
cultured for five days. Proliferation (measured by quantifying the 3H-thymidine 
incorporation in T-cells) was comparatively analyzed in cultures in which MSCs were 
present (ratio of 1:10 to the responder PBLs) or absent. (2) The suppressive capacity of 
MDSCs [190] was estimated by measuring the proliferation of purified, autologous T-
cells in response to anti-CD2/CD3/CD28-T-cell stimulating bead-coupled antibodies. 
For quantifying T-cell proliferation, T-cells were pre-labeled with carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) before the assay. CFSE diffuses passively into 
cells, where it interacts with intracellular esterases and amines and becomes 
fluorescent. The formed dye-protein adduct is maintained in the cell during meiosis and 
inherited by the daughter cells. The dilution of the dye upon proliferation was assessed 
by fluorescence activated cell sorting. 
7.2.2 FACS (Paper I-IV) 
Fluorescence activated cell sorting (FACS) has become an essential method in 
immunology. It allows the detailed monitoring of many facets of the immune system. 
In short, cells stained with fluorescence labeled antibodies or dyes are acquired in a 
laminar stream of fluid. The cells pass through a laser beam that allows (utilizing 
different lasers, filters and detectors) the simultaneous detection of the cell volume 
(forwards scatter (FCS)), cell granularity (sideward scatter (SSC)) as well as by 
measuring the emitting signal of the excited fluorescent dye, the expression of the 
target of interest. Fluorescent antibodies stain antigenic surface markers. The 
application of different fluorochromes in combination with the data gained by FCS and 
SSC makes it possible to distinguish different cells subsets. Furthermore, utilizing 
fixation/permeabilization reagents also intracellular expressed cytokines e.g. IL-10, IL-
17, IFN-γ and transcription factors such as FOXP3 or STAT can be analyzed. Besides 
phenotype, FACS gives the possibility to examine the viability (7-amino-actinomycin 
D (7AAD)/AnnexinV), proliferation (Ki67, CFSE) and the metabolism respectively 
oxidation status of cells. All above described application were utilized at some point in 
this thesis to analyze cell population in PBMCs [31, 51, 85, 190] respectively bone 
marrow cells [85] isolated by gradient based centrifugation.  
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7.2.3 ELISA and multiplex (Paper II and IV) 
Enzyme-linked immunosorbent assays (ELISAs) are a standard procedure to measure 
cytokines in serum or supernatant. The principle of the so-called sandwich ELISA is 
based on capture antibodies (bound to pre-coated micro plates), which bind one specific 
target antigen contained in the sample (in our studies IFN-γ, IL-10 and PGE2 in 
supernatants [31, 190]. After the binding incubation phase, unbound antigen is washed 
off and secondary specific antibody is added, to the wells. This secondary antibody is 
conjugated to an enzyme e.g. horseradish peroxidase. By adding the according 
substrate, the enzyme produces (depending on the amount of bound secondary 
antibody) a colored product. The resulting absorbance can be measured in a plate reader 
and the amount of target antigen quantitated employing a standard curve.  
Multiplex cytokine assays on the other hand allow the simultaneous analysis of 
multiple cytokines even in small volumes. This method was used to analyze serum 
samples of alloHSCT patients and the HLH patient [51, 85, 190]. This method utilizes 
microscopic small spheric, polysyrol particle (beads), which serve as binding phase 
similar to coated ELISA plates described above. Each assay contains a specified mix of 
bead populations, which are each coated with antibodies on the surface specific for one 
target analyte. Each bead population is again internally labeled with a defined 
concentration of a fluorescent dye. These different concentrations result in different 
emitting fluorescence upon excitation and allowing the discrimination of the 
population.  
In short, beads are incubated with the sample to allow binding of the respective analyte. 
Subsequently a biotinylated detection antibody is added, followed by the incubation 
with a streptavidin conjugate. This conjugate is bound to a fluorescent, which allows 
the specific detection of the amount of binding of the analyte. The conjugate has a high 
specific affinity to the analyte and emits a defined signal. Integrating all this 
information, allows the simultaneous classification of the beads and the quantification 
of the analyte in the sample. 
7.2.4 RT-PCR (Paper I, III) 
Real time polymerase chain reaction (RT-PCR) often synonymously termed 
quantitative real time PCR (qPCR) allows the detection and quantification of genes on 
the messenger RNA (mRNA) level utilizing complementary DNA (cDNA) synthesized 
from isolated total RNA.  
Cells were lysed utilizing RLT Buffer containing 0.01% β-Mercaptoethanol according 
to manufactures instruction (RNeasy Mini Kit, Qiagen Hilden). Cell lysates were stored 
at -80°C, if RNA isolation was not subsequently carried out. The technology of RNeasy 
Kits relies on (1) the lysis by denaturing guanidine thiocyanate which also inactivates 
RNases and (2) subsequent purification of RNA involving several centrifugation and 
washing steps in which RNA is bound to silica membranes. In the last step total RNA is 
eluted with RNAse free water. The obtained total RNA was stored at -80°C or 
immediately used for cDNA synthesis. cDNA synthesis requires two steps: (1) single 
stranded RNA is transcribed by the enzyme reverse transcriptase utilizing a RNA 
independent DNA-Polymerase and short oligonucleotide (primer); (2) obtained cDNA 
is amplified by conventional PCR (reverse-transcription PCR). Yielded cDNA was 
stored at -20°C. 
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During RT-PCR the amount of cDNA is measured in „real time“ with quantification 
at the end of each cycle. The quantification is detected by utilizing a fluorescent dye 
such as SYBR Green. SYBR Green intercalates with double stranded DNA (dsDNA) 
and emits a signal that correlates with the amount of dsDNA that was amplified by 
the according primer pair for the target gene.  
The gene expression can be normalized to the expression of a reference gene (house 
keeping gene). For all studies included in this thesis this was β-actin. Relative gene 
expression was calculated using the ∆∆-CT-formula: 
relative gene expression = 2^(ΔCT Target gene-ΔCT Reference gene) 
We used relative gene expression to monitor the impact of inflammatory licensing on 
the expression of immune regulating molecules such as HO-1, COX-2 and IDO in 
MSCs [31] and to elucidate the immunosuppressive mechanism of MDSC after 
alloHSCT [190].  
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8 RESULTS AND DISCUSSION 
MSCs have been widely evaluated within clinical studies and their efficacy and safety, 
in terms of an increased risk for infectious complications and/or acute toxicity, has been 
well demonstrated [11, 94, 323]. Since it is yet not unequivocally clarified, which 
mechanistic effects take place upon an adoptive transfer of MSCs, it is a difficult task 
to identify biomarkers that reflect the response to and/or the efficacy of MSC treatment. 
To date, most studies use the clinical response as the only parameter to value the 
(biological) impact of MSCs [94]. This obviously represents a hurdle, which needs to 
be overcome in order (1) to discriminate biological from clinical responses, (2) to 
develop biomarkers that identify good and bad responders towards MSC treatment, and 
(3) to optimize our application protocols and the patients’ outcome.  
As yet, most of our knowledge regarding the immunological effects of MSCs is based 
on in vitro observations and pre-clinical models. This self-evidently does not 
necessarily reflect the situation in patients. Aim of this thesis was to address the mode 
of action of MSCs focusing on the modulation of the adaptive immunity. Moreover, we 
attempted to transfer our in vitro observations into the translational clinical setting: (1) 
to better understand the in-patient MSC effects and (2) to deduct from these 
observations potential immunological biomarkers, which would allow to objectively 
assess the biological efficacy of transferred MSCs in the future. 
Briefly, in this thesis we were able to show that MSCs via TReg-induction directly and 
indirectly regulate T-cell responses. In doing so MSCs display a remarkable plasticity 
in terms of switching between different suppressive strategies, which is governed by 
their environment (Paper I). Furthermore, we observed that MSCs promote the 
skewing of monocyte polarization towards a regulatory M2 phenotype. This is of great 
importance for the experimental MSC treatment of diseases that are actually driven by 
inflammatory monocytes (such as HLH) (Paper II). In order to translate our findings 
from bench to bedside, we performed comprehensive immunome analyses in patients 
receiving MSCs and could de facto detect immune responses that were MSC-associated 
(Paper II, III, IV). Taken together our data support the notion that MSCs act in a “hit 
and run”-fashion [103]: infused MSCs elicit an immediate response (by e.g. releasing 
cytokines) that initiates an immunological cascade resulting in long lasting immune 
regulatory effects (Figure 3), which are active even after the disappearance of 
transfused MSCs. 
In the following sections the main results of my thesis are summarized. The 
information provided should help the reader to understand the scope of the performed 
published studies and the general implications of these findings. For more details on 
experimental set-up, results, and specific discussion of the findings, please refer to the 
appended articles. 
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8.1 TREG-INDUCTION BY MSCs - A MATTER OF PLASTICITY (PAPER I) 
The MSC-triggered promotion of immunosuppressive phenotypes in various immune 
cells, including the induction of TRegs from conventional T-cells has been demonstrated 
in several (in vitro and animal) studies [11, 29, 324]. 
Our initial interest was to investigate the impact of HO-1 on the MSC-mediated control 
of T-cell responses. HO-1 is a stress-responsive molecule with known anti-oxidative 
and immune modulating properties [325]. We found HO-1 to be highly expressed in 
human MSCs contributing to their resilience towards oxidative stress-induced cell 
death. This key feature allows them to remain operational in inflamed environments 
similar to the also immune modulating TRegs [235]. Since there were reports on HO-1 
being involved in the suppression of T-cells by rat MSCs [320], we speculated that 
human MSCs express also HO-1, which as a prototypical stress-responsive molecule 
might be up-regulated within an inflammatory environment leading to a stronger 
suppressive activity. 
In fact, we could show that human MSCs (1) inhibit T-cell proliferation and (2) 
promote the induction of TReg-(subsets) in a HO-1 dependent fashion. In contrast to our 
initial hypothesis, we noticed a significant reduction of the HO-1 expression when 
MSCs encountered an in vitro alloreactive, highly inflammatory environment. Counter 
intuitively this HO-1 down-regulation elicited by soluble factors was not accompanied 
by a reduced capacity for T-cell regulation. In fact, MSCs suppressed more potently T-
cells and induced more TRegs albeit HO-1 levels were very low. In order to understand 
this phenomenon we evaluated the impact of the inflammatory milieu on other 
important immune modulating molecules (e.g. IDO or COX-2) [33, 70]. Inflammatory 
conditioning of MSCs led to a dramatic up-regulation of COX-2, which was then 
central for their boosted ability to promote TReg generation. These findings are very 
much in line with the current dogma of MSCs being activated by inflammatory 
cytokines (e.g. IFN-γ or TNF-α) in a process termed as MSC-“licensing” [33, 35]. This 
is important for two reasons: (1) therapeutically applied MSCs will most likely 
encounter an inflammatory environment since nowadays inflammatory diseases 
represents their main indication and (2) it can be reasoned that a MSC-“licensing” prior 
administration could harness their therapeutic efficacy. Of course more in vitro and 
preclinical data as well as addressing regulatory issues (e.g. compliance with GMP 
standards) are obligatory before considering the clinical translation. In addition, we 
demonstrate that the same (suppressive) function within one cell type (MSCs) can be 
mediated by different molecules, in our case HO-1 or COX-2, depending on the current 
environment further highlighting the unique functional plasticity of MSCs. 
8.2 MYELOID CELLS AS A TARGET FOR MSC-BASED THERAPY 
(PAPER II) 
The failure to treat a disease with the means provided by conventional therapy is one of 
the strongest motivations to employ experimental approaches. This was the case in a 
young patient suffering from a rare autosomal recessive immunological disorder that is 
known as familial hemophagocytic lymphohistiocytosis (FHL). Defects in lymphoid as 
well as myeloid cells lead to hyper-inflammation, which is often triggered by normally 
harmless viral infections. The name FHL is derived from a characteristic bone marrow 
infiltration with monocytes/macrophages that phagocyte the hematopoietic cells 
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leading to severe cytopenias. Without immune suppressive treatment (e.g. 
chemotherapy and steroids) survival time is very low and the only curative treatment 
remains alloHSCT. 
The particular patient was treated for over several months with a combination of 
chemotherapy, steroids, and targeted anti-inflammation (=anti-TNF-α antibodies) 
without achieving disease control and while facing severe infectious complications. An 
alloHSCT was at this time not foreseeable due to the lack of a matched donor and 
sufficient disease control. After careful consideration we decided to treat the patients 
with an adoptive transfer of third-party MSCs. The transferred MSCs inhibited in in 
vitro pre-testing T-cell activation and more importantly promoted the differentiation of 
regulatory CD206+HLA-DRlowIL-10 producing M2 monocytes. This observation is 
very important since monocytes/macrophages play a decisive role in FHL 
pathophysiology. In fact and in addition to their hemophagocytic activity, it is widely 
assumed that suppressive M2 monocytes/macrophages in FHL patient represent a 
reaction - in terms of an inherent feedback-mechanism – to the systemic inflammation 
[326, 327]. Based on these promising biological properties we infused the MSCs 
without any signs of toxicity. In fact, we observed a fast decline of inflammatory 
cytokines (e.g. IL-15, which is produced by activated phagocytes) and FHL activity 
markers (e.g. serum triglyceride and ferritin levels), less IFN-γ producing T- and NK-
cells, and elevated IL-10 levels. Overall, several of the anticipated beneficial effects 
(based on the in vitro tests) in terms of T-cell and monocyte/macrophage modulation 
were confirmed ex vivo further strengthening our motivation for performing similar 
bench to bedside approaches always on the grounds of previously well-studied basic 
biology. In fact, treatment with MSCs might represent an option for patients with 
refractory FHL at least for bridging the time to alloHSCT and for potentially reducing 
the need for chemotherapeutics and the accompanying severe toxicities.  
8.3 REGULATORY CELLS AS BIOMARKERS IN MSC TREATMENT 
(PAPER III AND IV) 
As pointed out several times, we still lack an objective (bio-) marker for assessing the 
biological (in addition to the clinical) response of MSC treatment. In order to address 
this translational issue we performed a comprehensive analysis of the immune system 
of patients receiving therapeutic MSC infusions. These (screening) efforts included 
almost all main populations (T-cells, B-cells, NK-cells, DCs, and monocytes) and 
several key subsets (e.g. nTRegs, Tr1 cells, and MDSCs) of immune cells and several 
relevant cytokines (e.g. IL-2, IL-4, IL-10, and TNF-α) that could have been affected by 
MSCs based on previous reports from in vitro and/or animal studies [11, 22, 27, 28, 46, 
47, 49, 52, 54, 71, 328].  
Of note, we had the opportunity to perform our experiments on unique patient material: 
steroid-refractory GVHD patients enrolled in a randomized double blinded study 
receiving either MSC or placebo infusions. To our knowledge this was the first time a 
randomized control study available for investigating MSC associated effects on the 
immune system. Blood was drawn at 7, 30, 60 and 180 days following MSC or placebo 
application respectively. Shortly after MSC infusion we observed a significant drop of 
endothelial cell death products (serum cytokeratin 18 fragments), which represent a 
novel activity marker for GVHD [329]. This finding was very important for us, since it 
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proved that MSCs lead to a measurable (at least) non-specific reduction of the ongoing 
inflammation. Albeit our immune screening was rather broad T-cell analysis remained 
our focus since (alloreactive) donor T-cells hold a key role in initiating and driving 
GVHD but at the same time are decisive for elimination of residual tumor cells (=GVT 
effect) and protection from pathogens (e.g. viral infections). 
Reconstitution of T-cells in terms of numerical alterations was not affected by MSC 
infusion. However, we found a rather normal CD4+/CD8+ T-cell ratio in the MSC 
group. The placebo group on the other hand displayed an inversed ratio, which is often 
seen in alloHSCT patients. This observation together with a shift of the TH1/TH2-
balance towards TH2-responses further strengthens the notion that MSCs might act as a 
“reset button” leading to restoration of immunological homeostasis. Both, impact on 
CD4+/CD8+ as well as TH1/ TH2-ratio comes as a nice validation of results from animal 
studies [29, 30]. The induction of TRegs including their main subsets (nTRegs, Tr1 and 
Th3 cells) (Paper I) represents a key MSC feature for us. It would allow MSCs to 
prolong their suppressive action by generating another type of suppressive cells that 
most likely outlives the transferred cells [103] leading to some kind of “immunologic 
imprinting” (by MSCs). As a matter of fact, we found significant higher levels of nTRegs 
and Tr1 cells in the circulation of MSC treated patients. This observation is very much 
in line with findings from several in vitro and animal studies performed by others and 
us (Paper I).  
Our data strongly indicates that the reason for the elevated TReg levels was not an 
increased thymic output, but rather the proliferation of already pre-existing TRegs and/or 
their conversion from conventional T-cells respectively. In this context we found 
increased IL-2 levels in patients receiving MSCs, which has already be seen under in 
vitro conditions [330], but still requires a convincing mechanistic explanation. This 
finding is of particular importance taking into consideration that IL-2 is central for 
fitness and homeostatic proliferation of TRegs [331]. Remarkably, TReg frequencies 
correlated positively with the IL-2 serum concentrations in our treated patient cohort 
and current trials are actually testing the use of low-dose IL-2 in GVHD patients for 
promoting TRegs. Based on this data, one could speculate that MSCs might in the future 
redundantise approaches that exclusively aim in boosting the TReg compartment (e.g. 
IL-2 or adoptive TReg transfer). One outstanding commonality of all altered immune 
parameters was their transient nature as both, the placebo and MSC group, were almost 
equal six months after treatment supporting the more and more emerging concept of 
using sequential MSC applications. 
The so-called MDSCs are thought to represent the myeloid counterpart of TRegs. Our 
data (Paper II) and a recently published study [71] indicate that human MSCs when 
cultured together with monocytes promote a phenotype that resembles monocytic 
MDSCs as found accumulated in several tumor entities [187]. Of course we were 
interested in confirming these observations in the GVHD patients that had received 
MSCs (Paper III). Before doing so we first had to identify and characterize MDSCs in 
alloHSCT patient, which led to a number of interesting results (Paper IV). AlloHSCT 
patients have increased levels of monocytic CD14+HLA-DRlow/neg cells that suppress 
activation of autologous T-cells allowing us to term them MDSCs. The MDSC 
frequency peaked early after transplantation and early engraftment during a period that 
is characterized by (1) high levels of inflammatory cytokines (=so-called “cytokine 
  48 
storm”) and (2) (myeloid) growth factors as well as an (3) increased (“emergency”) 
myelopoiesis. These parameters have already been shown to be involved in MDSC 
accumulation and we could effectively notice a significant link between IL-6 
(=inflammatory cytokine) and G-CSF (=growth factor) with MDSC frequency. The 
MDSCs’ T-cell suppressive activity was mediated by IDO, which appears to be also 
systemically activated in alloHSCT patients [261]. An inhibition of IDO led in vitro to 
a partial restoration of T-cell function, which was corroborated by the ex vivo data that 
MDSC numbers were negatively associated with T-cells’ proliferative capacity, CD3ζ 
chain levels, and the expression of activation markers. Interestingly and despite their 
obvious T-cell suppressive function MDSCs were more abundant in more severe 
inflammatory GVHD, which is in line with a generalized activation of tryptophan 
metabolism during GVHD [332]. This finding could be indicative of a compensatory 
increase in regulatory MDSCs that however fail to control the overwhelming immune 
response that underpins GVHD.  
 
 
 
Figure 13: Accumulation of MDSCs in alloHSCT. Preparatory (radio-) chemotherapy 
(conditioning regimen) for alloHSCT leads to tissue damage and subsequent inflammation. In 
addition, alloreactive donor T-cells, which are fundamental for establishing the GVT effect 
regularly target healthy tissue (preferably the liver, skin, and gut) of the host, resulting in a 
highly inflammatory condition known as GVHD. The high levels of pro-inflammatory 
cytokines released in this setting stimulate MDSCs as part of a physiological mechanism for the 
control of inflammatory damage. This stimulation most likely represents a multistep process, 
including an increased mobilization of myeloid progenitors from the bone marrow, a 
differentiation arrest and the re-programming of mature myeloid cells mediate 
immunosuppressive functions. Accumulating monocytic MDSCs following alloHSCT express 
the enzyme IDO, which exerts suppressive effects on T-cells by depleting tryptophan and via its 
metabolites (e.g. kynurenine). Such immunosuppressive effects include the inhibition of T-cell 
proliferation and IFN-γ production as well as the downregulation of CD3ζ [333]. 
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Based on these results it can be speculated whether MDSC-based therapeutic 
approaches might represent an additional option for treating GVHD. Nevertheless, 
studies evaluating larger patient cohorts for longer observational periods are required to 
elucidate the actual potential of MDSCs in alloHSCT patients. First, we need to 
unequivocally clarify the impact of MDSCs on the risk of disease relapse (=GVT 
effect). Second, we have to assess whether MDSCs are linked to viral infection and/or 
reactivation, since an increasing number of publication suggests that viruses (e.g., 
hepatitis C virus) utilize MDSCs for escaping immunosurveillance. However, when 
returning back to our initial question regarding the impact of MSC infusion on the 
patients’ MDSC we did not detect any interconnection, which might be due to the 
strong MDSC-promoting inflammatory signals that overshadow the effects of MSCs. 
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9 CONCLUSIONS 
Nowadays, cellular therapy has emerged as a promising tool for boosting immune 
responses (e.g. T-cell transfer in cancer) or restoring immunological homeostasis (e.g 
TReg transfer in aGVHD). However, transferring living cells into patients naturally 
implies the risk for substantial, often unforeseen obstacles and consequences. A 
prerequisite for a successful cellular therapy is a thorough understanding of the 
involved immunological processes. Compared to HSCT, adoptive immunotherapy of 
MSCs is still in its infancy and its potential has certainly not been fully exploited. In the 
future, it will be an important task to elucidate the mode of action of MSCs in detail to 
ascertain the best way to employ them. 
 
In this thesis the following aspects of MSC biology and function were observed: 
 
MSCs possess potent antioxidative protective mechanisms and are not hampered by 
being cultured in an inflammatory milieu with abundant reactive oxygen species. 
 
MSCs utilize the antioxidative, cytoprotective enzyme HO-1 to induce TRegs in vitro. 
This function is even potentiated upon so-called “inflammatory licensing”. MSCs 
display a remarkable functional plasticity and while HO-1 loses its role during the 
licensing process, other molecules such as COX-2 take over its TReg-inducing capacity  
 
MSCs transferred in a patient suffering from HLH exhibited an immune regulating 
potential. The infusion of MSCs led to a fast reduction of inflammatory cytokines and 
reduced activation of T- and NK-cells. This was accompanied by a higher prevalence 
of myeloid cells with an immune regulatory phenotype and an increased release of IL-
10. 
 
Upon infusion into patients suffering from steroid-refractory aGVHD, we found that 
patients that had received MSCs exhibited higher levels of regulatory T-cells which 
correlated with increased IL-2 levels. The ratio of Th1/Th2-T-cell responses appeared 
more balanced and lower frequencies of Th17-cells were prevalent. The observed effect 
was transient as MSC treated patients exhibited similar levels after 6 months as placebo 
treated controls. MSCs did not negatively impact the immune reconstitution. 
 
When evaluating the myeloid compartment of patients that underwent alloHSCT we 
found regardless of MSCs a higher frequency of CD14+HLA-DRlow/neg cells. These 
cells correlated with time point after transplant as well as grade of aGVHD. Elevated 
frequencies correlated with reduced T-cell activation as well as reduced CD3ζ chain 
expression. These CD14+HLA-DRlow/neg cells suppressed T-cells in vitro utilizing IDO. 
Inhibition of IDO restored T-cell function and lead to upregulation of CD3ζ chain 
expression.  
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